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ABSTRACT
How proteins undergo conformational changes to bind a ligand is one of the most
fundamental questions of protein biology. MD simulations provide a useful
computational tool for studying the theoretical movements of protein in solution on
nanosecond timescales. The results of these simulations can be used to guide
experimental design. By correlating the theoretical models with the results of
experimental studies, we can obtain a significant amount of information about protein
dynamics. This study represents the application of both computational and traditional
experimental techniques to study protein dynamics in HIV-1 protease. The results
provide a novel mechanism for the conformational changes in proteins and address the
role of residues outside the active site in protein dynamics. Additionally, these results are
applied to the complex role of non-active site mutations in the development of drug
resistance.
Chapter II examines an invariant Thr80 at the apex of the P1 loop of HIV-1, HIV-
2, and simian immunodeficiency virus protease. Sequence variability associated with
human immunodeficiency virus type 1 (HIV-1) is useful for inferring structural and/or
functional constraints at specific residues within the viral protease. Positions that are
invariant even in the presence of drug selection define critically important residues for
protease function. Three protease variants (T80V, T80N, and T80S) were examined for
changes in structure, dynamics, enzymatic activity, affinity for protease inhibitors, and
viral infectivity. While all three variants were structurally similar to the wild type, only
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T80S was functionally similar. T80V significantly decreased the ability of the enzyme to
cleave a peptide substrate but maintained infectivity, while T80N abolished both activity
and viral infectivity. Additionally, T80N decreased the conformational flexibility of the
flap region, as observed by simulations of molecular dynamics. Taken together, these
data indicate that HIV-1 protease functions best when residue 80 is a small polar residue
and that mutations to other amino acids significantly impair enzyme function, possibly by
affecting the flexibility of the flap domain.
Chapter III focuses on residues within the hydrophobic core of each monomer in
HIV-1 protease. Many hydrophobic residues located in the core of this dimeric enzyme
frequently mutate in patients undergoing protease inhibitor therapy. The mechanism by
which these mutations aid the development of drug resistance is not well understood.
Using MD simulations, this study suggests that the hydrophobic residues outside the
active site facilitate the conformational change that occurs in HIV-1 protease upon
binding substrates and inhibitors. In these simulations, the core of each monomer
significantly rearranges to assist in the expansion of the active site as hydrophobic core
residues slide by each other, exchanging one hydrophobic contact for another. Such
hydrophobic sliding may represent a general mechanism by which proteins undergo
conformational changes. Mutation of these hydrophobic core residues would alter the
packing of the hydrophobic core. Thus, these residues could facilitate drug resistance in
HIV-1 protease by altering dynamic properties of HIV-1 protease preferentially affecting
the relative affinity for inhibitors versus substrates.
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Chapter IV concentrates on a residue in the flap region, Ile54, which is
significantly correlated with the development of drug resistance. A series of patient
sequences containing the mutation I54A were evaluated for the most frequently occurring
co-mutations. I54A was found to occur with mutations that were previously correlated
with I54V mutations, including L10I, G48V, and V82A. Based on the results of this
evaluation, the binding properties of five variant proteases were investigated: MDI54V,
MDRI54A, I54V, I54A, and G48V. MDRI54V and MDRI54A each contained the mutations
L10I, G48V, and V82A, and either I54V or I54A, respectively. The other variants
contained only the mutation indicated. Mutations at Ile54 were able to significantly
impact the thermodynamics of binding to saquinavir, amprenavir, and the recently
approved darunavir. The magnitude of this impact depended on the presence or absence
of other drug resistance mutations, including another mutation in the flap region, G48V.
Therefore, while residues 48 and 54 are not in contact with each other, mutations at both
sites had a cooperative effect that varies between inhibitors.
The results demonstrate that residues outside the active site of HIV-1 protease are
clearly important to enzyme function, possibly through their role in the dynamic
properties of protease. Mutations outside the active site of protease that are known to
cause drug resistance could alter the conformational flexibility of protease. While the role
of protein dynamics in molecular recognition is still not fully understood, the results of
this study indicate that altering the dynamic properties of a protein affects its ability to
recognize ligands. Therefore, to design better inhibitors we will have to develop a more
thorough understanding of protein dynamics.
ix
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1CHAPTER I
INTRODUCTION
2Our ability to answer some of the most fundamental questions of protein biology,
such as how proteins undergo conformational changes to bind a ligand, is limited by our
inability to view the dynamic movements of proteins at the nanosecond to second
timescales. Despite these limitations we are able to use various biophysical methods to
infer information about protein dynamics. This work represents the application of
biophysical techniques, such as isothermal titration calorimetry and molecular dynamics,
to examine the dynamic properties of proteins. By using Human Immunodeficiency Virus
type 1 (HIV-1) protease as our model system we can apply our results to the world wide
clinical problem of drug resistance.
AIDS: The Global Epidemic
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) and
World Health Organization (WHO) 2006 AIDS epidemic update, approximately 38.6
million people globally are living with HIV infection, 2.3 million of whom are children
(Figure 1.1). Despite global public awareness campaigns aimed at prevention, an
estimated 5 million people were newly infected with HIV in 2005. The statistics on the
spread of this infection are staggering and devastating and reflect that this disease is one
of the greatest public health crises of our time. Of the estimated 2.8 million people who
died of AIDS related deaths, approximately 14% were children under the age of 15. The
areas most affected are some of the poorest and most underdeveloped areas of the world.
3Of the 4.1 million new infections in 2005, 2.7 million occurred in sub-Saharan Africa and
almost 1 million in South and South-East Asia, compared with 43,000 in North America.
Curbing the spread of this infection requires a comprehensive approach that addresses
both prevention of further infections and treatment of current infections. Developing the
most effective treatments involves understanding how the virus works, and what areas of
the life cycle are the best targets for inhibitor development.
4Figure 1.1
5Figure 1.1: Global Prevalence of HIV-1 Infections
6Human Immunodeficiency Virus
Human Immunodeficiency Virus type 1 (HIV-1) is a single stranded +RNA
lentivirus from the Retroviridae family. Current theories suggest HIV-1 evolved from a
chimpanzee strain of Simian Immunodeficiency Virus that first infected humans in Africa
anywhere from 1959 to 1979 (Gao et al. 1999; Keele et al. 2006). This virus has been the
subject of intense scientific research for more than 20 years and many aspects of the viral
life cycle are well understood (Figure 1.2). HIV-1 attacks particular cell types in humans,
primarily within the immune system such as CD4+ cells, macrophages, and dendritic
cells. Once the virus attaches to a host cell, it fuses with the cell membrane releasing its
contents into the host cell. Using host cell machinery, the viral reverse transcriptase (RT)
generates double stranded DNA from the viral RNA. This process results in frequent
mutations within the genome due to the infidelity of RT and its inability to repair the
mismatched base pairs (Preston et al. 1988; Bebenek et al. 1989; Perrino et al. 1989; Ji et
al. 1992; Bebenek et al. 1993). This is one of the primary causes of the genetic diversity
of this virus. The double stranded DNA is transported to the nucleus where the viral
integrase participates in the incorporation of the DNA into the host cell genome. The host
cell then generates both the viral RNA and all the structural and functional proteins of the
virus, including the Gag and Gag-Pro-Pol polyproteins (Figure 1.3). The virion assembles
at the cell membrane and subsequently buds from the host cell, taking a portion of the
cell membrane with it. HIV-1 has evolved to efficiently use the host cell machinery for
rapid replication. The high replication rate of the virus is another cause of its genetic
7diversity. When it buds off the cell membrane the virion is not yet mature, and, therefore,
not yet infectious.
Maturation of the virus requires the cleavage of the Gag and Gag-Pro-Pol
polyproteins by the viral protease. By a mechanism that is still poorly understood, HIV
protease cleaves itself out of the Gag-Pro-Pol polyprotein and then performs the
subsequent cleavage steps to release the structural and functional proteins from the Gag
and Gag-Pro-Pol polyproteins. These cleavage reactions do not occur sequentially but do
occur in a tightly regulated order and with meticulous specificity (Pettit et al. 1998; Pettit
et al. 2005). These regulated and specific cleavage reactions are necessary for viral
maturation and for subsequent infection, making the viral protease an excellent target for
antiviral therapy. However, necessity to the virus is not the only reason protease is an
excellent target. The wealth of information that the field has been able to acquire
regarding this enzyme propels the search for new protease inhibitors.
8Figure 1.2
9Figure 1.2: General feature of the HIV-1 replication cycle (Turner et al. 1998)
10
Figure 1.3
11
Figure 1.3: Organization of the HIV-1 genome and virion (Frankel et al. 1998)
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HIV-1 protease
HIV-1 protease is a 22-kilodalton homodimeric aspartyl protease whose activity is
essential to the virus (Kohl et al. 1988; Seelmeier et al. 1988; McQuade et al. 1990). Each
monomer of this enzyme consists of 99 amino acids. Structurally, protease can be broken
into four regions: the dimer interface (residues 1-10, 90-99), the core of each monomer
(residues 11-22, 29-39, 61-80, 85-90), the flap region (40-60), and the active site
(residues 23-28, 81-84) (Figure 1.4). The flap region of protease is an anti-parallel ß-
sheet made up of residues 40-47 and 53-60, with residues 48-52 forming a loop at the tip
of the flap. Just under the flap region is the P1-loop (residues 78-81). While these
residues 78-80 do not contact substrates or inhibitors, they have an indirect role in ligand
binding through their contact with the flap region. The core region of each monomer
consists of both hydrophilic and hydrophobic residues. While many of the hydrophilic
residues are on the surface of the molecule, Val11, Ile13, Ile15, Ala22, Leu24, Leu33,
Met36, Leu38, Ile62, Ile64, Val75, Val77, Ile85, Leu89, Leu90, and Ile93 pack inside the
protein to form the hydrophobic core of each monomer. These residues do not contact
inhibitors or substrates, but possibly assist in ligand binding by facilitating
conformational changes in the protease. The structure of HIV-1 protease is highly
conserved despite high sequence variability. As previously mentioned, due to the high
replication rate of the virus and the infidelity of the viral reverse transcriptase, the
protease gene undergoes frequent mutation. Polymorphic substitutions are mutations that
occur regardless of the presence of inhibitor therapy. However, many mutations in all
13
regions of protease are specifically tied the selective pressure of inhibitor therapy (Figure
2.1, Table 3.1, Figure 4.1). Mutations in the active site can have an obvious role in drug
resistance by altering contacts with inhibitors. However, it is still unclear how mutations
outside the active site lead to drug resistance.
In order to cause drug resistance, a mutation must decrease the affinity of protease
for an inhibitor without disrupting the ability of protease to recognize and cleave its
substrates. HIV protease specifically recognizes and cleaves at least nine non-
homologous, asymmetric sites within the Gag and Gag-Pro-Pol polyprotein. Processing
of these polyproteins occurs in a regulated order and at specific rates that are necessary
for viral maturation. HIV-1 protease recognizes its substrates sites based on structural
homology (Prabu-Jeyabalan et al. 2000; Prabu-Jeyabalan et al. 2002). This theory was
developed based on crystal structures of an inactive variant of protease bound to peptides
based on various substrate sites. When these crystal structures were superimposed, the
substrates fit into a particular molecular surface termed the substrate envelope (Figure
1.5). Subsequent studies revealed a corresponding inhibitor envelope (Figure 1.5).
Furthermore, drug resistance seems to be correlated with regions where the inhibitor
envelope deviates from the substrate envelope (King et al. 2004). Inhibitors protrude
from the substrate envelope at contact points with specific residues in the active site
where drug resistance mutations are known to occur, such as Val82. This information has
led to the design of inhibitors that more accurately mimic protease substrates.
HIV protease was the first successful target of structure-based drug design
(Wlodawer et al. 1993). As our knowledge of protease structure and function has
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expanded so has our ability to develop better inhibitors . Despite this targeted
development, protease continues to adapt to evade inhibitors (Johnson et al. 2003). The
current design of protease inhibitors often uses crystal structures of a static protein bound
to inhibitors. However, there are numerous mutations outside the active site whose role in
drug resistance is not obvious from crystal structures. These mutations possibly exert
their effect by altering the dynamic properties of the HIV-1 protease. In order to develop
better inhibitors, we must understand the role of these non-active site mutations. This
study examines residues outside the active site and their role in protein dynamics.
15
Figure 1.4
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Figure 1.4: Structural features of HIV-1 protease. The dimer interface (residues 1-10, 90-
99) is colored cyan, the core of each monomer (residues 11-22, 29-39, 61-80, 85-90) is
colored grey, the flap region (40-60) is colored blue, and the active site (residues 23-28,
81-84) is colored red. The catalytic aspartic acids are displayed.
17
Figure 1.5
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Figure 1.5: From (King et al. 2002). (A) The substrate envelope calculated with GRASP
(Nicholls et al. 1991) from the overlapping van der Waals volume of four or more
substrate peptides. The colors of the substrate peptides are red, matrix-capsid; green,
capsid-p2; blue, p2-nucleocapsid; cyan, p1-p6; magenta, reverse transcriptase-
ribonucleaseH; and yellow, ribonucleaseH-integrase.
(B) The substrate envelope as it fits within the active site of HIV-1 protease. The α-
carbon trace is of the CA-p2 substrate peptide complex (Prabu et al. 1999).
(C) The inhibitor envelope calculated from overlapping van der Waals volume of five or
more of eight inhibitor complexes. The colors of the inhibitors are yellow, Nelfinavir
(NFV); gray, Saquinavir (SQV); cyan, Indinavir (IDV); light blue, Ritonavir (RTV);
green, Amprenavir (APV); magenta, Lopinavir (LPV); blue, Atazanavir (ATV); and red,
(TMC114).
(D) The inhibitor envelope as it fits within the active site of HIV-1 protease.
(E) Superposition of the substrate envelope (blue) with the inhibitor envelope (red).
Residues that contact the inhibitors where the inhibitors protrude beyond the substrate
envelope and confer drug resistance when they mutate are labeled.
19
Protein Dynamics
Currently, there is no general experimental method that illustrates in atomic detail
the movements of proteins. Nuclear Magnetic Resonance (NMR) spectroscopy allows for
the determination of the time scales of atomic fluctuations and relative atomic positions,
but it does not yet provide enough detail to determine the mechanism of conformational
changes in proteins. Additionally, the results are based on an ensemble of molecules the
solution and may miss subtle differences in dynamics in a single molecule. NMR has
provided valuable information on the picosecond- microsecond time scales of motion in
protease (Nicholson et al. 1995; Ishima et al. 1999) and how ligand binding affects these
motions (Yamazaki et al. 1994; Yamazaki et al. 1996; Ishima et al. 1999).  However,
NMR cannot yet provide a detailed mechanism how the protein changes during ligand
binding. In order to examine these atomic details, we use computational models based on
our knowledge of the physical forces that act on each atom within a protein.
Molecular dynamics (MD) simulations allow us to observe the movements of a
single molecule over short time scales (picoseconds- microseconds). Starting positions
for atoms in a molecule are frequently provided from crystal structures or NMR
structures. MD requires the knowledge of which atoms are bound together and which
atoms are in contact with each other to determine the forces on each atom in a molecule.
The molecule is then set in motion while atoms are restricted by these forces. This
method allows us to predict possible pathways through which proteins move and adapt to
their environment. MD has been used to examine how the protease flaps move to allow
20
substrate access to the active site and how mutations impact the conformational flexibility
of the flap region (Collins et al. 1995; Scott et al. 2000; Piana et al. 2002; Perryman et al.
2004; Meagher et al. 2005; Bandyopadhyay et al. 2006; Hornak et al. 2006; Perryman et
al. 2006; Toth et al. 2006; Toth et al. 2006). However, there has been limited discussion
of the role of residues outside the flap region in protease dynamics.
 This work uses MD to explore the role of residues outside the flap and outside the
active site in the conformational flexibility of protease. A previously published 10
nanosecond MD simulation reported a dramatic conformational change in the unliganded
protease (Scott et al. 2000). The flap tips of protease were shown to curl in towards the
P1-loop of protease, thereby exposing the active site for substrate binding (Figure 1.6).
These results were consistent with NMR results regarding the time scale of flap
movements. In the “flap curled” conformation, Ile50 contacted Thr80 in the P1-loop of
protease, suggesting a possible role for Thr80 in flap dynamics. Additionally, the 10
nanosecond MD simulation suggested that the flap region of protease was not the only
region to undergo significant conformational changes. The hydrophobic core of each
monomer underwent significant rearrangement that could play a role in substrate binding.
While this 10 nanosecond simulation provided insight into the flap dynamics involved in
substrate binding, it also raised interesting questions regarding the role of residues
outside the flap region in protein dynamics. The role of these residues is explored in the
following work.
21
Figure 1.6
0ns 1ns 2ns 3ns
4ns 5ns 6ns 7ns
8ns 9ns 10ns
22
Figure 1.6: Snapshots of the backbone conformation of HIV-1 protease throughout the
trajectory at 1 ns intervals. Adapted from(Scott et al. 2000)
23
Thermodynamics of Binding
When a protein binds to its ligand energy is either released or consumed. This
energy change often measured as a heat change upon binding. Isothermal titration
calorimetry (ITC) measures the heat change associated with ligand binding and uses this
information to determine both the enthalpy of binding (∆H) and the binding affinity (Ka)
between two molecules (Figure 1.7). From the measurements of ∆H and Ka, the free
energy of binding (∆G) and the entropy of the reaction (∆S) are calculated according to
the equations:
€ 
ΔG = −RT lnKa
and
€ 
ΔG = ΔH −TΔS
ITC was used extensively in this study to examine the impact of mutations on the
thermodynamics of binding between HIV protease and various protease inhibitors.
The thermodynamic parameters of binding measured using ITC represent not only
the interactions between the bound protease and the inhibitor, but also changes within the
protease, within the inhibitor, and within the solvent from going between the free state to
the bound state.  Each thermodynamic parameter has specific implications for the
binding. The change in enthalpy upon binding is related to the changes in atomic
contacts, such as hydrogen bonds and van der Waal contacts. For example, enthalpy of
binding is affected by hydrogen bonds that are broken or formed within protease, or
between protease, the inhibitor, and the solvent upon inhibitor binding. Entropy is related
24
dynamic properties of each component of the system. For example, the change in entropy
upon binding is related to the loss of conformational freedom for both protease and the
inhibitor caused by binding and related to the release of ordered water in the active site
upon inhibitor binding. By comparing the enthalpy and entropy of binding between
different protease inhibitors when binding particular protease variants we can obtain
information about how each inhibitor interacts with protease. Similarly, we can compare
the enthalpy and entropy of binding between protease variants to a particular inhibitor to
make inferences about how properties, such as protein dynamics, are affected by
mutations.  When the same inhibitor is used to study binding to different protease
variants, differences in the thermodynamics of binding can be attributed to changes in the
protease.  For example, when two protease variants bind the inhibitor saquinavir,
differences in the entropy of binding may represent differences in the conformational
flexibility of the protease variants. Therefore, by studying both multiple protease variants
and multiple inhibitors we can acquire a significant amount of information regarding the
conformational changes protease undergoes when binding inhibitors.
When comparing the thermodynamics of binding between different protease
variants and inhibitors, changes in ∆H often complement changes in ∆S, a phenomenon
referred to as enthalpy-entropy compensation. This refers specifically to changes
observed in the enthalpy that are matched by contrasting changes in the entropy of
binding. This phenomenon has been discussed frequently in the literature (Dunitz 1995;
Sharp 2001; Beasley et al. 2002; Blasie et al. 2004), and usually refers to differences of
1-2 kcal mol-1. However, enthalpy-entropy compensation in HIV protease can involve
25
changes on the order 5 kcal mol-1 or greater (Muzammil et al. 2003; Ohtaka et al. 2003).
Others have proposed that these enthalpy and entropy changes are due to the ability of
inhibitors to adapt to mutations (Ohtaka et al. 2005). However, this ignores the complex
changes that are occurring in HIV-1 protease due to these mutations. This study shows
that enthalpy-entropy compensation is directly correlated with mutations in HIV protease.
We further hypothesize that this compensation is related to changes in protein dynamics,
and these changes lead to drug resistance.
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Figure 1.7
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Figure 1.7: Sample Isothermal Titration Calorimetry curve. The top graph shows the heat
released in µcal sec-1 with each injection of the protease inhibitor saquinavir into a
protease solution. The lower graph displays the normalized heat change per injection in
kcal mol-1 of inhibitor added.
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 This study explores the role of residues outside the active site in protein
dynamics. Using MD simulations we are able to generate theoretical models of protein
dynamics. We can correlate these models with the changes observed in the binding
thermodynamics of variant proteases and protease inhibitors. Because the entropy of
binding is related to the dynamics properties of the system, we can use ITC to infer
changes in protein dynamics induced by mutations in HIV-1 protease.
Chapter II is a comprehensive analysis of the role of Thr80 in HIV-1 protease. As
previously mentioned, this residue was observed to interact with Ile50 at the tip of the
flap in a 10 ns MD simulation. Additionally, Thr80 is invariant in the general patient
population, implying it has an important role in either protease structure or function. In
order to probe the role of Thr80 in flap dynamics, the 10 nanosecond MD simulation was
continued with Thr80 mutated to three different residues, serine, valine, and asparagine.
The results of these simulations were then compared with experimental studies in order to
provide a comprehensive picture of the role of Thr80 protease flap dynamics.
Chapter III examines the role of the hydrophobic core in protease dynamics
through the analysis of MD simulations. A thorough investigation of two separate MD
simulations reveals that correlated movements between the hydrophobic residues in the
core of each monomer facilitate a conformational change in HIV-1 protease that may be
required for ligand binding.
Chapter IV uses ITC to explore the role of flap mutations in the development of
drug resistance. Residue 54 is in the flap region of HIV-1 protease but does not contact
substrates or inhibitors. Mutations at this site have been correlated with drug resistance,
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though the mechanism of this effect has not been explained. Perhaps Ile54 plays a role in
flap dynamics and mutation may induce drug resistance by altering the dynamic
properties of the flap region.
Taken together these studies indicate that residues outside the active site are
crucial for protein dynamics and mutations at these residues could alter the dynamic
properties of a protein. In the case of HIV-1 protease, changing the conformational
flexibility of the enzyme could affect inhibitor binding causing drug resistance.
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CHAPTER II
THE ROLE OF INVARIANT THR80 IN HUMAN IMMUNODEFICIENCY VIRUS
TYPE 1 PROTEASE STRUCTURE, FUNCTION, AND VIRAL INFECTIVITY
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Abstract
Sequence variability associated with human immunodeficiency virus type 1 (HIV-1)
is useful for inferring structural and/or functional constraints at specific residues within the
viral protease. Positions that are invariant even in the presence of drug selection define
critically important residues for protease function. While the importance of conserved active-
site residues is easily understood, the role of other invariant residues is not. This work
focuses on invariant Thr80 at the apex of the P1 loop of HIV-1, HIV-2, and simian
immunodeficiency virus protease. In a previous study, we postulated, on the basis of a
molecular dynamics simulation of the unliganded protease, that Thr80 may play a role in the
mobility of the flaps of protease. In the present study, both experimental and computational
methods were used to study the role of Thr80 in HIV protease. Three protease variants
(T80V, T80N, and T80S) were examined for changes in structure, dynamics, enzymatic
activity, affinity for protease inhibitors, and viral infectivity. While all three variants were
structurally similar to the wild type, only T80S was functionally similar. Both T80V and
T80N had decreased the affinity for saquinavir. T80V significantly decreased the ability of
the enzyme to cleave a peptide substrate but maintained infectivity, while T80N abolished
both activity and viral infectivity. Additionally, T80N decreased the conformational
flexibility of the flap region, as observed by simulations of molecular dynamics. Taken
together, these data indicate that HIV-1 protease functions best when residue 80 is a small
polar residue and that mutations to other amino acids significantly impair enzyme function,
possibly by affecting the flexibility of the flap domain.
40
Introduction
Human immunodeficiency virus-1 (HIV-1) protease is an enzyme crucial to the
life cycle of the virus(Kohl et al. 1988). Inhibition of the protease prevents viral
maturation, and thus further infection, making it a prime target in the treatment of HIV-1
infected patients(Henderson et al. 1988; Robins et al. 1993; Chou et al. 1996).
Unfortunately, HIV-1 mutates frequently due to the high replication rate of the
virus(Coffin 1995) and the infidelity of the reverse transcriptase(Roberts et al. 1988;
Roberts et al. 1989; Ji et al. 1992). The viral protease tolerates mutations in many areas of
the sequence, especially mutations that decrease the binding affinity of inhibitors without
affecting the ability of protease to recognize and cleave its nine processing sites within
the Gag and Gag-Pro-Pol polyproteins. Such mutations cause drug resistance. Many
studies have explored residues susceptible to mutation and their role in the development
of drug resistance (Erickson et al. 1996; Schinazi et al. 1997; Ariyoshi et al. 2003;
Muzammil et al. 2003; Ohtaka et al. 2003; Kantor et al. 2004; Kantor et al. 2004).
However, some amino acids in protease have not been observed to mutate, even in the
presence of inhibitor therapy (Shafer et al. 1999) (Figure 2.1). While these conserved
residues potentially play a crucial role in either the structure or the function of the
enzyme, few studies have explored the purpose of the invariant amino acids outside the
active site. Utilizing these residues could assist in the design of new classes of protease
inhibitors that may be less susceptible to developing resistance.
HIV protease, a homodimeric aspartyl protease, envelops its substrate when the
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flap region of each monomer closes down on the substrate sites within the Gag and Gag-
Pro-Pol polyproteins. In a 10-nanosecond molecular dynamics (MD) simulation of the
unliganded protease the tips of the flaps (residue 47-53) were observed to curl towards
the protease core like fingers curling toward the palm of a hand (Scott et al. 2000) (Figure
2.1b). When the tip of the flap curls inward, Ile50 contacts a number of predominantly
hydrophobic residues in its own P1 loop (residues 78-83). The only polar residue in this
region is the virtually invariant Thr80. Thr80 is one of only 27 (out of 99) residues that
are invariant in 99.9% of sequences within the Stanford University HIV Drug Resistance
Database (Shafer et al. 1999). The remaining 26 invariant residues include the catalytic
Asp-Thr-Gly triad, five other glycines, three prolines, both tryptophans, and the tyrosine.
Of the 536 HIV-1, HIV-2, and SIV protease sequences found in the Los Alamos National
Laboratory Database, residue 80 is one of only 10 residues invariant in 99.8% of the
population. Additionally, numerous crystal structures show that the side chain hydroxyl
group forms highly conserved hydrogen bonds with the backbone of residue 82. Other
studies have observed structural changes in the P1-loop when binding inhibitors and drug
resistant mutations at Val82 and Ile84 (Baldwin et al. 1995; Gulnik et al. 1995; Ala et al.
1998; Klabe et al. 1998; Munshi et al. 2000; King et al. 2002; Prabu-Jeyabalan et al.
2003; King et al. 2004). By examining invariant residues within this loop, we may
discover new ways to target protease inhibitor therapy. Interactions between Thr80 and
Ile50 could be important for destabilizing the burial of Ile50 in a hydrophobic pocket and
maintaining the mobility of the flap tips. Thr80 could be important for stabilizing the P1-
loop through its highly conserved hydrogen bond with Val82. While the role of this
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residue has not been previously studied, the observation that Thr80 is invariant indicates
it is likely important to protease structure and/or function.
In the present study we utilize various methods to study the role of Thr80. The
native Thr80 was mutated to asparagine, serine, and valine, to generate three protease
variants referred to as T80N, T80S, and T80V. The impact of Thr80 on HIV-1 protease
structure and function is investigated by a variety of biophysical methods including
circular dichroism spectroscopy, tryptophan fluorescence, protein crystallography,
molecular dynamics simulations, fluorescence resonance energy transfer, and isothermal
titration calorimetry. Additionally, the impact of these mutations on the virus is examined
using a viral specific infectivity assay. Taken together these data indicate that Thr80
plays an important role in enzyme activity and help to clarify why Thr80 does not mutate
in vivo.
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Figure 2.1
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Figure 2.1: HIV-1 protease colored by sequence conservation (Shafer et al. 2001).
Residues colored red are invariant in both untreated and treated populations of patients.
Those colored yellow are invariant only in the untreated population. Invariant glycine
residues are colored blue. The side chains of the catalytic aspartic acids (Asp25), Trp6,
Trp42, and Thr80 are displayed. a. The unliganded protease structure, 1HHP. b. Protease
structure following 9-ns MD simulation.
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Materials and Methods
Protease gene construction. The synthetic gene for the wild type HIV-1 protease
sequence was made using codons optimized for protein expression in Escherichia coli,
and included a substitution of Gln7Lys to prevent autoproteolysis (Rose et al. 1993).
Residue 80 was mutated from threonine to three different amino acids: asparagine, serine,
and valine. Mutagenesis was performed with the Stratagene® Quikchange™ Site
Directed Mutagenesis Kit, and confirmed by sequencing.
Protease expression and purification. The expression and purification of HIV-1
protease was previously described(King et al. 2004; Prabu-Jeyabalan et al. 2004). Briefly,
the HIV protease gene was cloned into the plasmid pXC-35 (ATCC) (Cheng et al. 1992),
which was transfected into E.coli TAP106. Transfected cells were grown in a 12 L
fermenter and, following protein expression, lysed to release the inclusion bodies
containing the protease(Hui et al. 1993). Inclusion bodies were isolated by centrifugation
and the pellet was dissolved in 50% acetic acid to extract protease. High molecular
weight proteins were separated from the desired protease by size exclusion
chromatography on a 2.1 L Sephadex G-75 superfine (Sigma Chemical) column
equilibrated with 50% acetic acid. Refolding was accomplished by rapidly diluting the
protease solution into a 100-fold excess of refolding buffer. Excess acetic acid was
removed through dialysis. Protein used for crystallization was further purified with a
Pharmacia Superdex 75 fast-performance liquid chromatography column equilibrated
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with refolding buffer.
Far-UV Circular Dichroism Spectroscopy. To determine the effect of mutations
on the secondary structure of protease, far-UV circular dichroism (CD) spectra were
measured for wild type (WT) and variant proteases with a JASCO J-810 spectrometer.
The temperature was maintained at 20 ºC using a Peltier temperature control device.
Measurements were made in a rectangular cell with a 1 mm path length. Each spectrum
was obtained by averaging three spectra recorded from 250 to 200 nm at a 0.5 nm data
pitch and a rate of 20 nm min-1. The response time for each point was 8 s and the
bandwidth was 2.5 nm. Protease concentrations were between 5 and 11 µM in a buffer
containing 10 mM sodium acetate at pH 5 and 2 mM Tris (2-carboxyethyl) phosphine
(TCEP). Buffer scans were subtracted from the sample scans. The mean residue
ellipticity (MRE), in units of mdeg cm2 dmol-1 was calculated according to the equation:
€ 
MRE = θ
10N ×C × l
where θ is the measured signal in mdeg, N is the number of residues, C is the molar
concentration of protein, and l is the path length of the cuvette.
Tryptophan Fluorescence. To further explore structural changes caused by
mutations at residue 80, tryptophan fluorescence was measured in the presence and
absence of saquinavir (SQV). Fluorescence was measured on a Photon Technology
International spectrofluorimeter at 25 °C. The excitation wavelength was 295 nm and the
emission spectrum was scanned from 300 to 500 nm in 1 nm steps. Protease
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concentrations were between 5 and 5.5 µM in a buffer containing 10 mM sodium acetate
and 2 mM TCEP at pH 5. Buffer scans were subtracted from the sample scans. Each
variant was also examined for changes in fluorescence upon binding inhibitor. Protease
solutions were equilibrated with 30 µM SQV prior to measurement. Buffer scans
containing SQV were subtracted from the sample scans.
Protein Crystallization. To look for more localized changes in the structures of the
proteases T80N and T80S were crystallized with SQV, yielding the structures SQVT80N
and SQVT80S.  Protein solutions between 1.16 and 1.75 mg ml-1 were equilibrated with 5-
fold molar excess of the inhibitor SQV. Crystals were grown using the vapor diffusion
hanging drop method. The reservoir solution contained 126 mM sodium phosphate pH
6.2, 63 mM sodium citrate, and 23-24% ammonium sulfate(King et al. 2002). The
crystallization screens yielded rectangular crystals with the longest dimension being 0.1
mm.
Crystallographic Data Collection. The crystals were mounted within 0.2 mm
Hampton cryo-loops and flash frozen over a nitrogen stream. Data were collected on an
in-house Rigaku X-ray generator with a Raxis IV image plate. 250 frames of 5 minute
exposures were collected per crystal with an angular separation of 1° and no overlap
between frames. Frames containing unprocessed raw data were indexed using Denzo and
scaled using ScalePack (Minor 1993; Otwinowski et al. 1997). The SQVT80N and SQVT80S
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crystals diffracted to 1.5 Å and 2.0 Å, respectively. Complete data collection statistics are
listed in Table 2.1.
Structure solution and crystallographic refinement. The crystal structures were
solved and refined using the programs within the CCP4 interface (Collaborative-
Computational-Project 1994). The structures of SQVT80N and SQVT80S were solved using
the molecular replacement program AMoRe (Navaza 1994). The coordinates of a wild
type protease variant in complex with substrate (PDB: 1F7A) (Prabu-Jeyabalan et al.
2000) were used as the starting model. Upon obtaining the rotation and translation
solutions, the molecular replacement phases were further improved by using ARP/wARP
(Morris et al. 2002) to build solvent molecules into the unaccounted regions of electron
density. Subsequently, interactive model building was carried out using O (Jones et al.
1990). Initial 2Fo-Fc and Fo-Fc maps unambiguously yielded the positions of SQV in
each complex. Conjugate gradient refinement using Refmac5 (Murshudov et al. 1997)
was performed by incorporating Schomaker and Trueblood tensor formulation of TLS
(translation, libration, screw-rotation) parameters (Schomaker et al. 1968; Kuriyan et al.
1991; Tickle et al. 1999). The working R (Rwork) and its cross validation (Rfree) were
monitored through out refinement. The geometry of the structure was assessed using
Procheck (Laskowski et al. 1993) at the end of each refinement round. The refinement
statistics are also shown in Table 2.1.
Isothermal Titration Calorimetry. To assess changes in the interaction between
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each variant and SQV relative to WT, the binding affinity and enthalpy of interaction
between each protease variant and SQV were measured using competitive displacement
ITC experiment (Sigurskjold 2000; Todd et al. 2000; Valzaquez-Campoy et al. 2001;
Ohtaka et al. 2002; King et al. 2004) on a VP- isothermal titration calorimeter (MicroCal
Inc., Northampton, MA). The buffer used for all protease and inhibitor solutions
consisted of 10 mM sodium acetate (pH 5.0), 2.0% dimethyl sulfoxide, and 2 mM TCEP.
A 25- 30 µM protease solution was saturated with twenty-nine 10 µl injections of 0.3
mM pepstatin. Pepstatin was then displaced from protease by adding twenty-nine 10 µl
injections of 0.25 mM SQV. Heats of dilution were subtracted from the corresponding
heats of reaction to obtain the heat due solely to the binding of ligand to enzyme. The
binding affinity and enthalpy of the interaction between the protease and SQV were
obtained by using the Origin7 software to subtract the enthalpy and binding affinity of
pepstatin from the final displacement reaction. Direct titration experiments of SQV were
performed for T80N because this variant did not bind pepstatin and the direct titration of
SQV versus this variant yielded high-quality results. Twenty-nine 10 µl aliquots of 0.2
mM SQV were injected into solutions containing 22- 40 µM protease. Data were
processed and analyzed using the MicroCal Origin7 software package. Final results
represent the average of three measurements.
Enzymatic Activity. Changes in catalytic activity of each protease variant were
assessed by measuring each variants’ ability to hydrolyze the fluorogenic substrate Arg-
Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-Arg (Molecular Probes,
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Eugene, OR) (Matayoshi et al. 1990). Fluorescence reactions were monitored by exciting
solutions at 340 nm and recording emitted light at 490 nm in a Photon Technology
International spectrofluorimeter. Substrate solution (190 µL) was placed in a 3 mm
rectangular cuvette and baseline fluorescence was measured. The reaction was initiated
by adding 10 µL of 2 µM HIV-1 protease solution. After 20 s (the time needed for
manual mixing), data points were acquired every 2 s. At substrate concentrations above
10 µM results were tainted by the inner filter effect (Copeland 1996). The fluorogenic
substrate was dissolved in 1 M sodium chloride, 0.1 M sodium acetate, 1 mM EDTA, 1
mM DTT, 4% DMSO and 1 mg/mL BSA at pH 4.7 and the experiments were done at 25
ºC. The baseline fluorescence of the substrate solution was subtracted from the reaction
fluorescence. The increase in fluorescence was monitored in real time and the reaction
was considered complete when there was no further increase in fluorescence. Initial data
analysis showed that the Km was above 10 µM and Km and kcat could not be separately
determined. Therefore, kcat/Km was determined using substrate concentrations below Km
(Copeland 1996). The increase in fluorescence over time was fit by Kaleidagraph (v 3.6)
to the equation:
€ 
y = m1 + m2 × (1− e
(−m3×x ))
where m1 is the initial fluorescence, m2 is the total increase in fluorescence, and m3 is
[E]×kcat/Km. For each protease variant that reacted with the fluorescent substrate, kcat/Km
was calculated at concentrations of 2, 5, and 10 µM substrate. The average kcat/Km was
calculated over nine values, three at each substrate concentration.
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Specific Infectivity (SpIn) Assay. The SpIn assay was performed as described in
Henderson, et al. (manuscript in preparation). Mutations were introduced into the
protease region of a plasmid subclone of the NL4-3 strain of HIV-1 using the
Quikchange™ strategy. The mutagenized subclone was verified completely by sequence
then introduced into a full length clone of NL4-3 called pNL-CH. Two clones of each
mutant were isolated, and the nucleotide sequence of protease confirmed. The
mutagenized plasmids were used to generate infectious virus by transfecting 293 cells
that were plated at a density 3×105 cells per well of a 24-well plate one day prior to
transfection. Triplicate transfections of 0.5 µg of each plasmid DNA were done with each
mutant plasmid using Fugene transfection reagent (Roche) according to the
manufacturer’s instructions. The parental wild type plasmid was transfected in parallel,
also in triplicate, for direct comparison with the mutants. After 48 h, virus-containing
culture supernatants were collected, clarified of cellular debris by centrifugation at 3000
× g and 4 ºC for 5 min, and then stored at –80 ºC. The amount of capsid protein (p24) in
the culture supernatants was measured by an enzyme-linked immunosorbent assay
(ELISA) using reagents available from the National Cancer Institute AIDS Vaccine
Program. The manufacturer's instructions were followed except samples were mixed with
SDS (final concentration 1% w/v) and incubated at 100 ºC for 5 min for virion lysis. All
samples were measured in duplicate at two dilutions, and the masses were calculated
from the standard curve using the average optical density of the duplicate measurements.
Virus particles were also analyzed by western analysis as described previously (Resch et
al. 2002) using a polyclonal anti-p24 antibody (NIH AIDS Research and Reference
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Reagent program, 4250). Briefly, virus particles in the medium supernatant of transfected
cultures were collected by centrifugation and lysed.  The lysed viral proteins were
resolved by polyacrylamide gel electrophroesis under denaturing and reducing
conditions, and the proteins were then transferred to a membrane and probed with an
anti-p24 antibody.
The infectivity of the mutant viruses was measured by infecting TZM-bl cells
(AIDS Research and Reference Reagent Program, National Institutes of Health) that were
seeded at 1.3×104 cells per well of a 96-well plate 24 h prior to infection. After a 48 h
incubation with the virus, the cells were washed with 150 µL of Dulbecco’s phosphate
buffered saline, then lysed with 50 µL of luciferase reporter lysis buffer (Promega) and
stored at –80ºC. The samples were subsequently thawed. The amount of luciferase
activity present was quantified over a 4 second interval when 50 µL of luciferase reagent
(Promega) was injected in each well using a Floustar fluorescence plate reader (BMG
Labtech) to record the number of relative light units (RLU) emitted. SpIn, calculated as
the number of RLU per nanogram of infecting capsid protein, was normalized to the
parental strain, which was given a SpIn value of one.
Molecular Dynamics. To study the impact of mutating residue 80 on the
conformational flexibility of HIV-1 protease, separate MD simulations were run for WT
and three protease variants: T80S, T80N, and T80V. The initial coordinates were taken
from the 9 ns time point of a previous simulation where the protease flap tips were
already folded in towards the P1-loop (Scott et al. 2000). Each mutation (serine,
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asparagine, and valine) was modeled by MIDAS (Ferrin et al. 1988) into residue 80 in
both monomers, and MD simulations were started using the AMBER8 software package
(Case et al. 2004). Histidine residues were protonated at the epsilon nitrogen. 200 cycles
of restrained steepest descent energy minimization were performed on each structure. The
protein was restrained with a harmonic force constant of 9.55 kcal mol-1 Å-2. Each
structure was solvated using a TIP3P water box to allow for at least 8 Å of water on each
face of protease. The initial periodic box dimensions were 82.2 by 82.6 by 80.4 Å3.
Approximately 14,000 water molecules were added to each system and 1000 cycles of
steepest descent energy minimization were performed keeping the protein fixed.
Equilibration of the system continued with 5000 steps of restrained MD with a 9.55 kcal
mol-1 Å-2 force constant, and constant temperature (300 K) and pressure (1 atm). This
equilibration was followed by 25,000 steps of unrestrained MD. The data collecting
portion of the simulation was performed at constant temperature and pressure for 5 ns
using 1 fs time steps.
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Table 2.1
Parameter SQVT80S SQVT80N
Data Collection
Space group P212121 P212121
Z 4 4
a (Å) 50.50 50.52
b (Å) 57.93 58.18
c (Å) 61.62 61.52
Resolution (Å) 2.0 1.5
Total number of reflections 88158 123033
Number of unique reflections 12625 29647
Rmerge (%) 7.3 4.2
Completeness (%) 99.1 99.3
I/σI 8.2 17.7
Refinement:
Rwork value (%) 17.6 17.1
Rfree (%) 23.2 19.8
Rwork + Rfree (%) 17.9 17.3
RMSD
    Bond length (Å) 0.008 0.005
    Bond angles (°) 1.6 1.4
Number of waters 130 193
Number of Phosphates 5 6
Protein Data Bank Code 1FGU 1FGV
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Table 2.1: Crystallographic statistics of variant HIV-1 proteases, T80S and T80N, in
complex with saquinavir
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Results
The role of residue 80 in the structure, function, and viral infectivity of HIV-1
protease was investigated in three variants: T80N, T80V, and T80S.
General Structural Changes. Effects of the three mutations on the secondary
structure of HIV-1 protease were probed by far-UV circular dichroism spectroscopy.
Since HIV-1 protease is a predominantly ß-sheet protein, any mutation that dramatically
disrupted the structure would decrease the ß-sheet content of the protein and increase its
mean residue ellipticity (MRE) at 216 nm. As shown in Figure 2.2a, the three variants
had similar secondary structure to WT, comparable to previously published results(Xie et
al. 1999). The spectrum of T80V was almost identical to the WT protease and, within the
accuracy of protein concentration measurements, T80S and T80N were similar to that of
the WT. The overall resemblance among these spectra indicates that these proteases were
all folded similarly.
To further examine any structural changes caused by mutations at residue 80,
tryptophan fluorescence was measured for all variants. Each protease monomer has two
tryptophans: Trp6 at the dimer interface and Trp42 at the end of the flap region (Figure
2.1). The fluorescence of the native tryptophans was measured for WT protease and each
variant in the presence and absence of saquinavir (SQV). The emission spectra for T80V,
T80S, and T80N were similar to WT indicating that the tryptophans in the Thr80 protease
variants are in a similar environment to those in WT protease (Figure 2.2b). For both WT
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and variant proteases, the presence of SQV led to a 10% decrease of the observed
tryptophan fluorescence, suggesting that SQV is interacting with all these proteases.
However, these results did not provide information on how this interaction may have
been altered by mutation at Thr80.
Thermodynamic Parameters of Inhibitor Binding. To reveal any altered
interactions between SQV and the Thr80 variant proteases the binding affinity and
thermodynamic parameters of each variant and WT to SQV were determined by
isothermal titration calorimetry (Table 2.2). SQV was chosen because it is a well-
characterized first generation protease inhibitor(Krohn et al. 1991; Roberts 1995;
Maschera et al. 1996; Ermolieff et al. 1997; Hong et al. 2000; Cote et al. 2001;
Valzaquez-Campoy et al. 2001). SQV is an entropically driven inhibitor. As SQV is a
fairly hydrophobic molecule, it likely causes surrounding water molecules to become
ordered. The favorable entropy observed in the reaction between HIV-1 protease and
SQV is presumably due to the release of this ordered water when SQV is sequestered
within the active site of protease. The free energy of the binding of T80N and SQV was
4.2 kcal mol-1 less favorable than between WT and SQV. This decreased binding affinity
was associated with larger changes in the enthalpy and entropy of the reaction. The
entropy of T80N binding to SQV was 13.4 kcal mol-1 more favorable than WT, while the
enthalpic contribution was 17.7 kcal mol-1 less favorable. Similarly, a small decrease in
the binding affinity between T80V and SQV was associated with larger changes in the
enthalpy and entropy of the reaction. While the free energy of the reaction between T80V
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and SQV decreased by 0.5 kcal mol-1 relative to WT, the entropy of SQV binding was 4.5
kcal mol-1 more favorable and the enthalpy of the reaction was 5.0 kcal mol-1 less
favorable than its binding to WT. In contrast to the other two variants, there was no
change within error in the free energy of the reaction between T80S and SQV relative to
WT. While the entropy of T80S binding SQV was 0.4 kcal mol-1 more favorable than WT
binding SQV, the free energy of the reaction was maintained at approximately the same
value by 0.7 kcal mol-1 less favorable enthalpy. The thermodynamic parameters of all
reactions were measured using SQV. Therefore, the changes in enthalpy and entropy
were likely due exclusively to changes in the free and bound state of the enzyme between
the variants. Both the Thr80Val and Thr80Asn mutations decreased the binding affinity
of protease for SQV, and all three mutations affected the thermodynamics of the binding
between protease and SQV, demonstrating the importance of Thr80 in protease activity.
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Figure 2.2
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Figure 2.2: General structural features of WT and variant proteases (WT: black,
T80V: red, T80N: yellow, T80S: green). a. Far-UV circular dichroism spectra of WT and
variant proteases. b. Tryptophan fluorescence spectra of WT and variant proteases,
unbound and bound to SQV. The unliganded WT protease is shown as a solid line, and
the unliganded variant proteases as filled symbols. The WT protease bound to SQV is
shown as a dotted line, and the variant protease as empty symbols.
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Table 2.2
Variant Ka (M
-1) Kd (nM)
Kd
Ratio
ΔH
kcal mol-1
ΔΔH -TΔS
kcal mol-1
Δ(-TΔS) ΔG
kcal mol-1
ΔΔG
wild type (2.0 ± 0.1) × 109 0.50 ± 0.03 3.6 ± 0.1 –16.1± 0.1 –12.5± 0.4
T80S (1.5 ± 0.1) × 109 0.66 ± 0.03 1.3 4.2 ± 0.1 0.6 –16.5± 0.2 –0.4 –12.3± 0.3 0.2
T80V (8.8 ± 0.1) × 108 1.1 ± 0.01 2.3 8.6 ± 0.2 5.0 –20.6± 0.2 –4.5 –12.0± 0.1 0.5
T80N (1.3 ± 0.1) × 106 760 ± 25 1.5×103 21 ± 1.0 18 –29.5± 1.0 –13 –8.2± 0.2 4.3
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Enzymatic Activity. An assay of enzymatic activity was used to further verify the
importance of Thr80 to protease function. Each variant protease was examined for
deleterious effects on activity relative to WT through comparison of the ability of each
variant to cleave a fluorogenic MA-CA substrate. Both WT and T80S completely cleaved
all fluorescent substrate within 10 minutes (Figure 2.3a). The T80V required more than 2
hours to completely cleave all the substrate. The T80N was not able to cleave the
substrate. The catalytic efficiency, kcat/Km, for WT and T80S was 7.4×10-2 µM-1s-1 and
8.4×10-2 µM-1 s−1, respectively (Table 2.3), indicating similar catalytic activity for these
proteases. The kcat/Km of the T80V was 4.5×10-3 µM-1s-1, a 16-fold decrease relative to
WT. The impact of the Thr80Val and Thr80Asn mutations on protease activity further
confirms the importance of Thr80 in protease function.
Viral Infectivity. A Specific Infectivity (SpIn) assay of viral fitness was
performed using the Thr80 mutants to provide information about the proteases’ ability to
cleave the substrate sites necessary for viral maturation. Both the T80S-virus and the
T80V-virus were measured to be within two-fold as infectious as the WT-virus. The
apparent discrepancy between the enzymatic activity and the specific infectivity was
probably due to the fact that the MA-CA cleavage site is not the rate determining step in
viral maturation(Tözsér et al. 1991; Pettit et al. 1998; Maguire et al. 2002; Pettit et al.
2002). This indicates that despite impaired activity versus the MA-CA site, T80V was
still able to cleave other sites with sufficient efficiency to maintain near wild type levels
of infectivity.  In contrast the T80N-virus gave very low levels of infectivity. When we
examined the extent of processing by western analysis (Figure 2.3b) we found that the
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T80N-virus were composed of mostly unprocessed Gag, similar to a D25A protease
active site mutant virus.  In contrast, the T80S-virus and the T80V-virus were composed
of Gag that had been largely processed although to a lesser extent than the WT-virus.
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Figure 2.3
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Figure 2.3: Mutation at residue 80 affects protease activity. a. Enzymatic activity. The
increase in fluorescence over time observed when a 10 µL of a 2 µM protease solution
was mixed with 190 µL of 2 µM fluorescent substrate. Both WT (black) and T80S
(green) completely cleaved the fluorescent substrate within 10 minutes. The initial burst
in fluorescence occurs during the 20 seconds required for mixing. T80V (red) required 10
minutes to reach the same fluorescence the WT and T80S variants achieved in the first 20
seconds. The T80N (yellow) variant had virtually undetectable increases in fluorescence.
b.   Western analysis of mutant virus particles. Lane 1, pNLCH used as the wild type;
Lane 2, T80S mutant; Lane 3 another clone of the T80S mutant; Lane 4 T80V mutant;
Lane 5 T80N mutant; Lane 6 another clone of the T80N mutant; Lane 7 D25A active site
mutant of the protease used as a control for a negative processing phenotype; size
markers were included on the gel and their migration is shown on the right.
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Table 2.3
Variant kcat/Km (µM
-1 s-1)
wild type (7.4 ± 0.5) × 10-2
T80S (8.4 ± 1.3) × 10-2
T80V (4.5 ± 2.0) × 10-3
T80N No Detectable Activity
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Structure of Protease-Saquinavir Complexes. The Thr80Asn mutation consistently
impaired protease activity, while the Thr80Ser mutation did not affect protease activity.
To determine what structural changes were causing the observed effect on protease
activity, T80N and T80S were crystallized with SQV yielding the two structures, SQVT80S
and SQVT80N, with 2.0 Å and 1.5 Å resolution, respectively. These structures were
submitted to the Protein Data Bank and assigned the PDB codes 1FGU and 1FGV for the
SQVT80S and SQVT80N respectively. The electron density for both SQV and the mutated
side chains was unambiguous and there were no crystal contacts between the mutated
side chains and surrounding protease molecules. The crystallographic statistics for these
structures are listed in Table 2.1. The Protein Database structure of wild type HIV-1
protease bound to saquinavir (PDB code 1HXB)(Krohn et al. 1991) has saquinavir in two
orientations. In order to obtain the most accurate comparison between structures, and
because T80S behaved just as WT, the SQVT80N and SQVT80S structures were compared
with each other. To look for changes between the SQVT80N and SQVT80S structures,
difference distance plots using the Ca backbone of each structure were generated
comparing the two protein variants (Figure 2.4). This plot shows that one monomer of the
SQVT80N structure underwent significant structural rearrangement to accommodate
asparagine, while the other monomer was able to accommodate the larger side chain
without altering the position of the main chain atoms of protease.
While residue 80 is not in the active site of protease, it is bound to and contacts
residues directly involved in ligand binding. Therefore, a mutation at this residue could
cause significant rearrangement of the protease with inhibitor bound. As shown in the
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double difference distance plot, the distance between residues Pro79-Val82 and most
regions of the protein increased by more than 0.5 Å in SQVT80N relative to SQVT80S. The
most significant increases were with residues in the both flap regions, Lys43-Gln58 and
Lys43’-Gln58’, and the P1-loop in the opposite monomer, Pro79’-Val82’. In SQVT80N the
side chain of Asn80 folded back on itself (Figure 2.5a). Relative to Ser80, this
conformation of Asn80 increased its interaction with Val32 and Leu33 and formed a
hydrogen bond between Asn80 OD and Pro79 N. The side chain amide nitrogen of
Asn80 and the side chain carboxyl oxygen of Ser80 maintained the conserved hydrogen
bond with the backbone oxygen of Val82. However, the conformation of Asn80 altered
the P1-loop relative to its position in SQVT80S pulling Pro81 back from the 2-methyl-
decahydro-isoquinoline-3-carboxylic acid-P1’ (DiqP1’) group of SQV and Val82 towards
DiqP1’. In SQVT80N, SQV lost a contact with Pro81, which was above it, when the
distance between Pro81 CG and DiqP1’C5 increased by 0.7 Å, and gained a contact with
Val82, which was below it, when the distance between Val82 CG1 and DiqP1’ C6
decreased by 0.9 Å in SQVT80N relative to SQVT80S. Figure 2.6b shows contacts that
decreased by more than 0.2 Å in SQVT80N relative to SQVT80S, and the opposite
information in displayed in Figure 2.6a. These results emphasize that structural
rearrangement of the P1-loop can significantly alter the interactions between protease and
SQV.
Though one monomer of the SQVT80N structure had rearranged the P1-loop relative
to SQVT80S, the other monomer did not undergo any repositioning of its main chain atoms
relative to the SQVT80S structure. As shown in the double difference plot, the distance
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between 80’ Ca and other residues was not significantly different between the SQVT80N
and SQVT80S structures, indicating that, when the protease variants were bound to SQV,
the protease was able to accommodate asparagine at residue 80’. Asn80’ adopted a
similar conformation to Ser80’ (Figure 2.5b) and both residues formed the same
hydrogen bonds with the main chain atoms of Pro81’ and Val82’. A significant difference
between the two structures was the presence of a water molecule in the SQVT80N structure
between Ile50 and residues Pro79’-Pro81’ that was not observed in the SQVT80S structure.
This water forms one hydrogen bond with the side chain amine group of Asn80’, one
contact with SQV, and numerous contacts with both main chain and side chain atoms of
Ile50, Pro79’, Asn80’, and Pro81’. Despite the increased size of asparagine and the
presence of the extra water molecule there was remarkable similarity of this monomer
between the structures. However, there was some structural rearrangement of SQV and a
few variations in the van der Waal contacts made between the protease and SQV. There
was one contact between Asn80’ and the phenylalaninol-P1 (HphP1) group of SQV not
observed in the SQVT80S structure. Conversely, the distance between Pro81’ and the
HphP1 and 2-carbonylquinoline-P3 (QncP3) groups was increased by more than 0.2 Å in
SQVT80N relative to SQVT80S. Two van der Waal contacts were lost between SQV and the
SQVT80N variant protease due to this increased distance (Figure 2.6). This indicates that,
in contrast to the structural rearrangements observed by residues Pro79-Val82, the altered
interactions between SQV and protease in this monomer are due to rearrangements of
SQV to accommodate Asn80’.
Interactions between SQV and the protease flap region differed between SQVT80N
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and SQVT80S.These changes were caused by the structural modifications that were made
either by the P1-loops or SQV. For example, in the SQVT80S structure, the DiqP1’ group
has the most van der Waal contacts with the flap region, while in the SQVT80N structure
the asparagine-P2 (AsnP2) group of SQV had the most contact with the flap region. The
QncP3 group of SQV was closer to Gly48 and AsnP2 moved closer to Ile50’ in SQVT80N
relative to their distance in SQVT80S. Thus substitution of asparagine at residue 80 was
able to indirectly affect the flap region in the bound protease.
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Figure 2.4
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Figure 2.4: Difference distance plots of SQVT80N versus SQVT80S. Relative changes in the
distance between two alpha-carbon atoms in the SQVT80S structure versus SQVT80N
structure. Green, blue, and red contours distinguish the ranges −1.0 to −0.5 Å, 0.5 to 1.0
Å, and 1 Å and above, respectively.
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Figure 2.5
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Figure 2.5: P1-loops of the crystal structures of SQVT80N and SQVT80S superimposed. Side
chain oxygen atoms are shown in red and side chain nitrogen atoms in blue. Water
molecules within 5 Å of residue 80 are shown as van der Waal spheres. a. Asn80
(SQVT80N: yellow; SQV: orange) and Ser80 (SQVT80S: green; SQV: cyan) adopt very
different conformations in the P1-loop. b. Asn80’ and Ser80’ adopt similar
conformations, and the P1-loops in this monomer are not significantly different between
the two structures. The modeling program MIDAS (Ferrin et al. 1988) was used to
superimpose the two protease structures, SQVT80N and SQVT80S, based on the highly
conserved terminal region (1-9 and 86-99).
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Figure 2.6
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Figure 2.6: Differences in van der Waal contacts between protease and SQV in the
SQVT80S and SQVT80N crystal structures. Distances between these two structures that
changed by more than 0.2 Å were considered significant. Side chain oxygen atoms are
shown in red and side chain nitrogen atoms in blue. a. van der Waal spheres are used to
show contacts between protease atoms and SQV atoms that decreased by more than 0.2 Å
in SQVT80S relative to SQVT80N. b. van der Waal spheres are used to show contacts
between protease atoms and SQV atoms that decreased by more than 0.2 Å in SQVT80N
relative to SQVT80S.
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Flap Dynamics Changes. In order to further examine the role of residue 80 on the
structure and conformational flexibility of the flap region of the unbound protease, a
separate molecular dynamics (MD) simulation was performed for WT and each variant
protease, T80V, T80N, and T80S. Each simulation was started from the 9 ns structure of
the previous MD simulation (Scott et al. 2000) since the flap region was already folded in
towards the P1-loop in this structure. Because these were relatively short simulations and
nothing was restraining the protease, the two monomers in each simulation exhibit two
conformational samplings of protease monomers. Figure 2.7 shows four time “snapshots”
from the four simulations at 0 ns, 1.5 ns, 3 ns, and 4.5 ns. The WT, T80S, and T80V
simulations sampled similar conformational space. Though each monomer moves
separately, in all three simulations the protease flap region unfolds into the solvent. To
quantify the range of motion of the protease flaps in each simulation the distance between
residue 50 and residue 80 in both monomers in all simulations was monitored over time.
In the WT, T80V, and T80S simulations the distance between these two residues
fluctuated between 5 and 22 Å in both monomers. In one monomer of the T80S
simulation the space sampled by the flap region was significantly decreased, relative to
WT and its other monomer, due to a hydrogen bond between the backbone oxygen of
Pro79 and the backbone nitrogen of Ile50. After approximately 3.5 ns that hydrogen bond
was broken, and the flap began to unfold into the solvent. In contrast to the other
simulations, the flaps within the T80N simulation did not unfold into the solvent. As
shown in Figure 2.7, there was decreased flexibility in both flap regions in the T80N
simulation relative to the other protease variants. The distance between Asn80 and Ile50
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fluctuated between 7 and 17 Å in one monomer, and between 6 and 8 Å in the other
monomer. In this simulation, the flap region with decreased movement was bound to the
P1-loop by two hydrogen bonds: one between the side chain oxygen of Asn80 and the
backbone nitrogen of Gly49, and the other between the backbone oxygen of Pro79 and
the same backbone nitrogen of Gly49. In the other monomer, there was not a specific
hydrogen bond between the flap region and the P1-loop, yet this flap remained curled
towards the P1-loop for the majority of the simulation. This was probably due to water
bridging hydrogen bonds between the flap and Asn80. These results demonstrate that
substituting a large polar residue for threonine at residue 80 can significantly and
detrimentally affect the conformational flexibility of the flap region. However,
substitution with a non-polar residue did not impact the ability of the protease flap to
unfold into the solvent.
As mentioned previously, there is a conserved hydrogen bond between the side
chain of residue 80 and the backbone of residue 82. In these simulations, the existence of
this hydrogen bond over time was monitored, except in the T80V simulation where no
hydrogen bond can exist. In the WT simulation, this hydrogen bond existed less than 10%
of time, and in the T80S simulation it existed less than 1% of the time. It did not exist in
the T80N simulation. As is shown in Figure 2.7, this hydrogen bond was not required to
maintain the stability of the P1-loop.  These simulations provide interesting insights into
the impact of variation at residue 80 on protease dynamics and may help to explain the
results seen in the various activity assays described above.
79
Figure 2.7
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Figure 2.7: “Snapshots” from the four MD simulations at 0.0, 1.5, 3.0, 4.5 ns (WT: black,
T80V: red, T80S: green, T80N: yellow). The flap region in the WT, T80V, and T80S
simulations unfolded into the solvent within 4.5 ns. In the T80N simulations the flap
region was less mobile.
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Discussion
Many residues within HIV-1 protease are susceptible to mutation, especially
under the selective pressure of therapy; therefore, those residues that are invariant despite
therapy are likely important to enzyme structure and/or function. Thr80, which is
invariant in HIV-1, HIV-2, and SIV proteases, regardless of protease inhibitor treatment,
is one such residue. While not directly involved in ligand binding, it is located on the
edge of the active site cavity in the middle of the P1-loop. To examine the role of this
residue in protease, we constructed three protease variants, T80S, T80N, and T80V, and
used a variety of biochemical techniques to characterize its role in the structure,
dynamics, and function of protease. Additionally, a viral infectivity assay was used to
examine the impact of changes at residue 80 on the virus as a whole. The results indicate
that mutation at this site can detrimentally impact the enzymatic activity, decrease viral
infectivity, alter the enthalpy and entropy contributions to inhibitor binding, and likely
decrease the conformational flexibility of HIV-1 protease.
Of the three variants studied, T80S had the least impact on protease structure and
function. This variant had a slightly increased kcat/Km relative to WT, but no substantial
change in its affinity for SQV and only an approximately two fold affect on viral
infectivity. Thus this mutation does not appear to give the virus any selective advantage
nor cause any resistance to SQV. Further studies are needed to clarify why Thr80Ser does
not occur as a natural variant. Regardless of the amino acid at residue 80, all protease
variants had similar structure to WT (Figure 2.2). Two variants, T80S and T80N, were
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crystallized with the inhibitor SQV. The structures were remarkably similar except that
the Thr80Asn mutation led to a structural rearrangement of the P1-loop in one monomer
relative to the SQVT80S structure (Figure 2.5) that altered the van der Waal contacts
between the T80N relative to the T80S (Figure 2.6). Despite the rearrangement of this
loop, the asparagine at this site was able to form hydrogen bonds with Val82. In fact,
maintenance of this hydrogen bond may be what led to the rearrangement of the P1-loop
in this monomer. The hydrogen bond between the side chain of residue 80 and the
backbone of Val82 was also observed in the other monomer of SQVT80N and in both
monomers of SQVT80S. Thus an important role of Thr80 in the bound protease appears to
be the formation of this hydrogen bond possibly to stabilize the P1-loop structure.
While this hydrogen bond was conserved in the crystal structures, it was not
conserved in the molecular dynamics (MD) simulations of unbound protease. MD
simulations were performed on all variant proteases and on the WT. In the WT, T80S,
and T80N simulations residue 80 was capable of forming a hydrogen bond between its
side chain and the backbone of Val82. However, this hydrogen bond existed only
intermittently in the WT and T80S simulations, and did not exist in the T80N simulation.
Without the hydrogen bond between residue 80 and Val82 the P1-loop itself was still
structurally stable. Actually residue 80 appeared to have the most significant impact on
the flexibility of the flap region. In the WT, T80S, and T80V simulations the flap region
uncurled into the solvent (Figure 2.7). This was somewhat surprising in the T80V
simulation because our original hypothesis was that the polar Thr80 prevented Ile50 from
packing into the hydrophobic pocket formed by other residues surrounding the P1-loop.
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Unexpectedly the polar asparagine at residue 80 prevented the flap from uncurling by
forming electrostatic interactions with the flap region limiting its flexibility. While crystal
structures of the bound protease would not suggest that residue 80 is involved in flap
dynamics, MD simulations illustrate a potential role for this site in flap dynamics.
Although residue 80 is not in the active site of protease, it is bound to and
contacts numerous residues involved in ligand binding. Therefore, mutations at this site
could have an indirect role in the function of protease. The examination of T80V and
T80N indicates that Thr80 may not mutate to less chemically similar amino acids due to
significant effects on protease activity. The catalytic efficiency of T80S, T80V and WT
was determined using a fluorescently labeled peptide substrate whose sequence is based
on the MA-CA site of HIV-1 protease (Matayoshi et al. 1990). The catalytic efficiency of
T80N versus this substrate could not be measured. While T80S had essentially WT
activity, T80V only retained 6% of the protease ability to cleave the MA-CA site. In
order to examine the impact of these mutations at residue 80 on the virus as a whole, the
specific infectivity of each variant was determined. Expectedly, the T80N-virus was not
infectious. However, the T80S-virus and T80V-virus were within two fold as infectious
as WT-virus and had only slightly decreased processing of Gag relative to WT-virus. The
discrepancy between specific infectivity and catalytic efficiency results is likely due to
the fact that the MA-CA cleavage is not the rate-determining step in viral maturation.
Previous work using 14 fluorescently labeled peptide substrates of HIV-1 protease
determined that the catalytic efficiency of the WT protease cleaving the MA-CA site was
320-fold more efficient than the cleavage of the NC-p1 site (Maguire et al. 2002).
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Mutations within the protease differentially impact the processing of the various
substrates and perhaps the Thr80Val mutation in protease does not affect the rate
determining cleavage steps in viral maturation as dramatically as it affects the cleavage of
the MA-CA site.
The role of residue 80 in HIV-1 protease was further elucidated by examining a
combination of crystal structures, molecular dynamics simulations, and isothermal
titration calorimetry. Through isothermal titration calorimetry we found that the inhibitor
SQV binds 2.3-fold more weakly to T80V than WT and 1500-fold more weakly to T80N.
In each case the decrease in binding affinity is due to a much less favorable enthalpy of
the interaction which decreased by 5 and 17.7 kcal mol-1, respectively, for T80V and
T80N. This decrease possibly indicates a structural change in the bound state or protease
between the variants, as seen in the crystal structure of T80N where there was an obvious
rearrangement of the residues in one of the P1 loops. The significantly less favorable
enthalpy for both protease variants is partially compensated by large favorable changes in
the other component of the binding energy, the entropy, with ∆(-T∆S) increases of –4.5
and –13.4 kcal mol-1for T80V and T80N, respectively. One hypothesized reason for
enthalpy-entropy compensation in other systems was a difference in the amount of bound
water molecules from one variant to another that does not affect the overall binding
affinity drastically, but does affect the entropy-enthalpy balance(Dunitz 1995; Sharp
2001; Beasley et al. 2002; Blasie et al. 2004). While this may account for 1-2 kcal mol-
1changes in enthalpy and entropy, the huge entropy-enthalpy compensations observed in
the case of T80V and T80N are probably due to a combination of effects.
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In the case of the Thr80 variants, changes in the thermodynamics are likely due to
changes in the enzyme since the ligand, SQV, and the solvent were constant between the
reactions. For T80V, the mutation of the polar threonine to the hydrophobic valine could
explain the observed changes in the enthalpy and entropy. The loss of enthalpy in this
case could be due to the inability of valine to form internal hydrogen bonds within the
protease structure, while the increase in entropy could be due to the release of ordered
waters solvating the hydrophobic valine upon forming a complex with SQV. More
ordered water would be needed to solvate the hydrophobic valine than needed to solvate
the polar threonine, thus more water would be released from the active site of T80V when
binding SQV.  Additionally a valine would have more conformational freedom as it is not
restricted by a hydrogen bond to the backbone.  Both asparagine and threonine are polar
residues, but asparagine is larger and capable of forming polar interactions with residues
in the flap region. In the case of T80N, the –13.4 kcal mol-1 more favorable entropy could
be due to the change in the flap dynamics that was observed in the molecular dynamics
simulation of the unliganded form of the enzyme.  In contrast with the other protease
variants, where the flaps are very flexible and a large loss of conformational entropy
within the protease occurs upon forming a complex, the flaps of T80N are much less
flexible.  Therefore, there is less conformational entropy to lose with T80N, and the
binding would be entropically more favorable than with the other variants. Thus
combining the results of these biophysical measurements, the molecular role of Thr80 to
HIV-1 protease is to have a small hydrophilic residue that facilitates flap flexibility in the
unliganded state, while allowing tight packing of the active site in the liganded state of
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the enzyme. This mechanism may therefore account for the importance and observed
invariance of Thr80 within HIV-1 protease.
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CHAPTER III
HYDROPHOBIC SLIDING FACILITATES CONFORMATIONAL CHANGES AND
ACTIVE SITE CLEFT OPENING IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
PROTEASE
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Abstract
Residues outside the active site of HIV-1 protease frequently mutate in patients
undergoing protease inhibitor therapy. These include many hydrophobic residues located
in the core of this dimeric enzyme. The mechanism by which these mutations aid the
development of drug resistance is not well understood. This study suggests that the
hydrophobic residues outside the active site facilitate the conformational change that
occurs in HIV-1 protease upon binding substrates and inhibitors. Using MD simulations,
19 residues were determined to be part of the hydrophobic core of the protease. In these
simulations as the flaps separate, simultaneously the core of each monomer significantly
rearranges to assist in the expansion of the active site. The hydrophobic core residues
slide by each other, exchanging one hydrophobic contact for another, while maintaining
many structurally important hydrogen bonds. Such hydrophobic sliding may represent a
general mechanism by which proteins undergo conformational changes because the
exchange of one hydrophobic van der Waal contact for another hydrophobic contact can
occur with little energetic penalty. Mutation of these hydrophobic core residues would
alter the packing of the hydrophobic core, affecting the conformational flexibility of the
protease. Because ligand binding and release is a dynamic process, we further propose
that mutations at these sites could contribute to drug resistance by altering the dynamic
properties of HIV-1 protease preferentially affecting the relative affinity for inhibitors
versus substrates.
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Introduction
Human Immunodeficiency Virus type 1 (HIV-1) protease is a symmetric
homodimeric aspartyl protease that cleaves a series of ten non-homologous and
asymmetric substrate sites in the Gag and Gag-Pro-Pol polyproteins allowing the virus to
mature and become infectious. In the liganded conformation of HIV-1 protease, two flaps
close over the active site, thereby encompassing the ligand (Figure 3.1b). A crystal
structure of the unliganded protease (Spinelli et al. 1991) shows the flaps of the enzyme
extended, yet still touching each other at Ile50 (Figure 3.1a). However, this conformation
is possibly stabilized by a crystal contact from a symmetry related molecule (Spinelli et
al. 1991; Scott et al. 2000). While it is clear that these flaps must separate for a substrate
to access the active site, the method by which the substrate gains access to the active site
remains unclear. Numerous studies have explored the movement of the flap region (Harte
et al. 1992; Collins et al. 1995; Ishima et al. 1999; Scott et al. 2000; Freedberg et al.
2002; Katoh et al. 2003; Perryman et al. 2004; Meagher et al. 2005; Bandyopadhyay et
al. 2006; Hornak et al. 2006; Perryman et al. 2006; Toth et al. 2006; Toth et al. 2006) but
few have explored the role of domains outside the active site and flap region in substrate
binding (Rose et al. 1995; Zoete et al. 2002; Muzammil et al. 2003; Ohtaka et al. 2003;
Perryman et al. 2004; Perryman et al. 2006). Many residues outside the active site and
flap region are often associated with drug resistance and, somehow have a role in ligand
binding. This role may be to facilitate the conformational changes that occur in HIV-1
protease to allow ligand binding.
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Each monomer of HIV-1 protease is made up of 99 residues, 40 of which are
hydrophobic (Figure 3.1). Some of these hydrophobic residues line the active site of the
protease making close van der Waal contacts with the ligand, while others are in the flap
region. A third category of residues encompasses the core hydrophobic cluster within
each monomer of the protease. Within the set of core residues are seven isoleucines,
whose side chains can adopt a large number of conformations (Ishima et al. 2001). As
these isoleucines change conformations, they could initiate conformational changes in the
protease through interdependent exchanges of van der Waal contacts. Many residues
within the hydrophobic core are associated with drug resistance (Johnson et al. 2004;
Rhee et al. 2005). For example, Leu33Phe is a primary mutation for tipranavir resistance
and a secondary mutation for all other inhibitors except saquinavir and nelfinavir
(Johnson et al. 2005). Protein crystal structures show that this residue is not in contact
with either substrates or inhibitors, but is packed deeply into the hydrophobic core
(Figure 3.1). Therefore its role in drug resistance is not obvious. The role of other such
core residues in the development of drug resistance is similarly unclear.
We hypothesize that the hydrophobic residues within the core, such as Leu33,
facilitate the large conformational change between liganded and unliganded
conformations of the protease as one hydrophobic surface slides by another with a
minimal energetic expense. Through an analysis of molecular dynamics (MD)
simulations, we found 19 residues in the core region of HIV-1 protease that had limited
solvent accessibility throughout the simulation. Further analysis of these MD simulations
revealed that these hydrophobic core residues facilitate the opening of the active site
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cavity to allow for substrate binding. Mutations in the core likely affect the dynamic
properties of HIV-1 protease and potentially affect the ability of protease to bind
inhibitors and substrates. Therefore, mutations in this region that preferentially affect
inhibitor binding over substrate binding would cause drug resistance and may explain the
role of these residues in the development of drug resistance.
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Figure 3.1
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Figure 3.1: Conservation of hydrophobic residues. Only the hydrophobic residues in
HIV-1 protease are displayed. Residues colored red are completely conserved, those
colored blue only mutate to other hydrophobic residues, and cyan colored residues mutate
to hydrophilic residues. Yellow circles are used to highlight Leu33. a. Unliganded crystal
structure of HIV-1 protease (PDB: 1HHP). b. Liganded crystal structure of protease
(PDB: 1F7A)
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Methods
GROMOS molecular dynamics simulation.  Three separate MD simulations were
run using the GROMOS96 (van Gunsteren et al. 1996; Scott et al. 1999) simulation
package and the 43A1 force field with the SPC water model (Berendsen et al. 1987) were
used in all simulations. Bond lengths were constrained using the SHAKE algorithm
(Ryckaert et al. 1977) with a relative geometric tolerance of 10-4. A twin-range pairlist of
8 and 14 Å was employed in the non-bonded force calculations that was updated every 10
fs. A Poisson-Boltzmann reaction field (Tironi et al. 1995) correction term was employed
in the Coulomb interactions. Temperature was maintained at 300K and pressure was
maintained at 1 atm using the Berendsen weak coupling approach (Berendsen et al.
1984). A time step of 2 fs was employed in the leapfrog integration scheme (van
Gunsteren et al. 1977). In the first simulation, the crystal structure of 1HHP was solvated
with 5843 water molecules in a truncated octahedron periodic box (MD1HHP). The second
and third MD simulations were started from the crystal structure of 1F7A. First, the
structure was solvated with 7334 waters in a truncated octahedron periodic box (MDSUB).
In a separate simulation, the substrate from this crystal structure was removed and the
protein was solvated with 7381 waters in a truncated octahedron periodic box (MDNOSUB).
A steepest descent minimization was performed with the protein atoms harmonically
restrained to their X-ray positions. Initial atom velocities corresponding to a temperature
of 300 K were generated from a Maxwellian distribution for an equilibration molecular
dynamics (MD) run of 10 ps, keeping the harmonic restraints in place. The system was
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equilibrated for a further 500 ps without harmonic restraints. A simulation of 5 ns was
performed for data collection, with coordinates and energies saved every 1 ps. The
MD1HHP was carried out for another 4 ns.
The first nanosecond of all three simulations was considered equilibration time
and was not included in the analysis. The backbone alpha-carbon fluctuations relative to
the starting structure were calculated for all three simulations between 1–5 ns. The
coordinates at each ps were also examined to look for the presence of hydrogen bonds
between 1-5 ns in all the simulations, and the percentage of time these hydrogen bonds
existed was calculated.  In order to determine which residues were part of the
hydrophobic core, coordinates at every 0.5 nanoseconds in through out the entire MD1HHP
simulation were examined for hydrophobic residues with limited solvent accessibility.
Hydrophobic residues not solvent-accessible for the majority of the simulation were
defined as part of the hydrophobic core.
AMBER molecular dynamics simulation. The 9 ns coordinates of the GROMOS
simulation were used as the starting structure for this simulation performed with the
AMBER8 software package (Case et al. 2004). These coordinates were stripped of the
solvent and 200 cycles of restrained steepest descent energy minimization were
performed restraining the protease with a harmonic force constant of 9.55 kcal mol-1 Å-2.
The protease was then solvated using a TIP3P water box to allow for at least 8 Å of water
on each face of protease. The initial periodic box dimensions were 82.2 by 82.6 by 80.4
Å3. Approximately 14,000 water molecules were added to each system and 1000 cycles
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of steepest descent energy minimization were performed keeping the protease coordinates
fixed. Equilibration of the system continued with 5000 steps of restrained MD with a 9.55
kcal mol-1 Å-2 force constant, and constant temperature (300 K) and pressure (1 atm). This
equilibration was followed by 25,000 steps of unrestrained MD. The data collecting
portion of the simulation was performed at constant temperature and pressure for 5 ns
using 1 fs time steps. Coordinates at every 0.5 ns were examined for changes in
hydrophobic contacts.
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Results
Obtaining an atomic view of the concerted movements of a protein is not easily
achievable by any experimental technique. Therefore, solvated molecular dynamics
simulations were performed to observe the conformational flexibility of HIV-1 protease
under three different starting conditions. Two simulations were started from the crystal
structure of a substrate complex of HIV-1 protease (PDB entry code 1F7A) (Prabu-
Jeyabalan et al. 2000; Prabu-Jeyabalan et al. 2002), one with the substrate (MDSUB) and
the other without the substrate (MDNOSUB). These simulations were run for 5 nanoseconds
and appeared to have reached a local minimum. The other simulation, MD1HHP, was
started from the unliganded crystal structure (PDB entry code 1HHP). This simulation
was performed for 9 nanoseconds. While MDNOSUB had slightly larger fluctuations in
peripheral regions of the protein relative to MDSUB, the flexibility of the protease in
MD1HHP was much greater than either of the two simulations started from the substrate
bound coordinates in the time period sampled (Figure 3.2). The flap region in MD1HHP
and the amino terminus of protease in MDSUB had the largest fluctuations, consistent with
what has been seen by NMR (Ishima et al. 1999; Hong et al. 2000; Todd et al. 2000;
Ishima et al. 2001; Freedberg et al. 2002). Based on the correlation between MD1HHP,
MDSUB and NMR results, we concluded that the force field is reasonable and the
conformations sampled in the MD1HHP are not likely an artifact of the simulation. To
further examine the significant changes observed in MD1HHP, this simulation was
continued for another 5 nanoseconds using the AMBER8 software package (Figure 3.3).
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By examining the protease in two force fields we determined that the changes observed
were not an artifact of the GROMOS simulation. Additionally, because the two
monomers that started in the same conformation underwent different conformational
changes, we were able to examine two possible pathways for protease dynamics. In order
to determine what was causing these changes, we began a detailed analysis of atomic
interactions in these simulations.
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Figure 3.2
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Figure 3.2: Relative fluctuations (Å) of the alpha-carbon atoms during 1 - 5 ns. The
fluctuations of each structure relative to the starting coordinates were mapped onto a
ribbon diagram of each structure using coordinates from the simulations. The backbone is
colored based on the degree of fluctuations. Residues colored blue had greater than 0.4 Å
fluctuations, those colored purple greater than 0.55 Å fluctuations, magenta 0.7 Å, orange
0.85 Å, and yellow greater than 1 Å fluctuations. a. MDSUB. b. MDNOSUB. c. MD1HHP.
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Figure 3.3
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Figure 3.3: Snapshots of HIV-1 protease during the MD1HHP simulation. The catalytic
aspartic acids are displayed and colored black. Residues 11-22 are colored magenta, 31-
38 colored red, 39-57 colored blue, 58-78 colored cyan. 1-10, 22-24, 25-32, and 79-99
are colored grey. a. Starting coordinates. b. After 9 ns in the GROMOS96 force field. c.
After an additional 5 ns in the AMBER force field.
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Maintenance of hydrogen bonds provides structural stability. As a protein undergoes
conformational changes it might be possible for one set of hydrogen bonds to be
exchanged with another or with solvent with very little energy cost to the protein, as long
as the total number of bonds remains constant. However this is not what is observed in
the simulations. Throughout the MDSUB and MDNOSUB simulations, and the first 5 ns of the
MD1HHP simulation, any hydrogen bonds that exist were tracked using geometrical
considerations of distance and angle between the donor and acceptor atoms over time. In
Figure 3.4 all the hydrogen bonds that were both formed greater than 50% of the time
between the first and fifth nanoseconds of the trajectory and found in all three simulations
are shown. Despite the increased fluctuations of the protease in MD1HHP, many hydrogen
bonds were maintained, although for a slightly smaller percentage of the time. Most of
these hydrogen bonds were among backbone atoms. In fact, the bonds appear to maintain
the secondary structure of the protease intact as the enzyme moves.
In order to compare the simulations with experimentally determined structural
information, six crystal structures of HIV-1 protease bound to substrates were examined
for side chain hydrogen bonds that were conserved between the structures (Prabu-
Jeyabalan et al. 2000; Prabu-Jeyabalan et al. 2002). Only five side chains in each
monomer maintained conserved hydrogen bonds among these structures and these same
side chains maintained hydrogen bonds in all three simulations more than 50% of the
time in both monomers. These five residues, Asp/Asn25, Thr26, Thr31, Asn83 and
Asn88, are highly conserved among viral isolates. Only Asn88 mutates 9% of the time,
usually to aspartic acid or serine, under the pressure of inhibitor therapy(Shafer et al.
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1999). Two of the residues, the catalytic Asp25 and Thr26 (which is involved in a
"fireman's grip" with itself on the dimer interface), have been extensively studied by
other groups (States et al. 1982; Wallqvist et al. 1998). The other three residues, Thr31,
Asn83, and Asn88, form a network of conserved side chain hydrogen bonds that
effectively cap off the hydrophobic cluster within the monomers from the solvent
environment (Figure 3.4d) and are likely essential to the structural integrity of the
protease.
While many significant hydrogen bonds were maintained throughout the
simulations, the unliganded protease undergoes a considerable conformational change in
MD1HHP. In order to determine the mechanism of this change, we thoroughly examined all
the inter-residue contacts in the MD1HHP simulation. The examination of this simulation
revealed that hydrophobic residues in the core of protease exchange contacts with each
other and that these exchanges may lead to the conformational changes observed.
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Figure 3.4
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Figure 3.4: Hydrogen bonds maintain the structure of HIV-1 protease. The coordinates at
every picosecond between 1 and 5 nanoseconds of the GROMOS simulation were
analyzed for the existence of hydrogen bonds based on the angle and distance between
the donor and acceptor atoms. The percentage of time each bond existed was calculated
and mapped onto coordinates from the simulation. Bonds are colored based on the
percentage of time they existed. Bonds colored black existed for more than 80% of the
time, those colored green for more than 60% of the time, and yellow for more than 50%
of the time. Nitrogen atoms are colored blue, and oxygen atoms are colored red. Side
chains involved in conserved hydrogen bonds are displayed and colored cyan. These
include Thr26, Thr31, His69, Asn83, and Asn88. a. Liganded HIV-1 protease simulated
with the substrate bound. The grey box represents the area displayed in part d. b.
Liganded HIV-1 protease simulated with the substrate removed. c. Unliganded HIV-1
protease. d. Hydrogen bonds involving residues Thr31, Asn83, and Asn88. The carbon
atoms in these residues are colored magenta. The residues of the hydrophobic core are
also shown with van der Waal spheres.
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Residues within the hydrophobic core. To determine which residues comprised
the hydrophobic core, a detailed structural analysis was performed at every 0.5 ns in the
MD1HHP simulation to look for residues whose sidechains were buried for the majority of
the simulation. This analysis revealed nineteen hydrophobic residues with especially
limited solvent accessibility. These residues, along with their mutational frequencies in
patient sequences, are shown in Table 3.1. There are seven isoleucines in the core of each
monomer. Isoleucine, whose sidechain has more possible conformations than leucine or
valine, appears to provide increased flexibility to the monomer. As the isoleucine
sidechains rotated through different conformations, they facilitated dramatic changes in
the hydrophobic core observed in these simulations.  Five of these isoleucines mutate in
the patient population, regardless of inhibitor therapy (Table 3.1). However, they only
mutate to other hydrophobic residues, most frequently valine. This implies that
maintaining hydrophobic interactions in this core is essential to HIV-1 protease function.
In order to examine why these hydrophobic interactions are important we examined the
changes in the hydrophobic core over time using MD simulations.
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Table 3.1
Position 5 11 13 15 22 24 33 36 38 62 64 66 75 77 85 89 90 93 97
Wild Type
Amino Acid
L V I I A L L M L I I I V V I L L I L
Untreated Patients (%) 0 0 38 24 0 0 2 55 0 12 15 0 0 15 0 47 0 30 0
Treated Patients (%) 0 0 27 23 0 5 6 43 0 26 21 1 0 26 3 18 31 36 0
Most Frequent
Mutation
- - V V - I F I - V V F - I V M M L -
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Table 3.1: Frequency of mutation of the residues in the hydrophobic cluster among
untreated and treated patients (Shafer et al. 1999; Johnson et al. 2005; Rhee et al. 2005).
Numbers are listed as the percentage of sequences that had another amino acid at this site.
Those listed in red cause drug resistance, those in blue contribute to drug resistance, and
those in bold italics are invariant.
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Rearrangement occurs within the hydrophobic cores. The conformational changes
of the protease in the MD1HHP simulation included a variety of changes throughout the
protein. In order to aid in the analysis and description of these movements, four loops
were highlighted in different colors in Figures 3.3 and 3.5. The flap region, which
consists of residues 39-57, was colored blue. This region is not part of the hydrophobic
core, though it is attached at either end to loops involved in the core. Just before the flap
region is a short loop comprising residues 31-38 (red). A larger loop made up of residues
58-78 (cyan), stems from the other end of the flap region. The last loop consists of
residues 11-21 (magenta). The two monomers, which were in the same conformation at
the start of the simulation, rearranged differently indicating that more than one physically
reasonable conformation of the protease was accessible. Within the first 9 ns, the flap
region slid back and the tips of each flap curled into each active site. This coincided with
a significant rearrangement of the hydrophobic core as the other three loops all dropped
relative to their starting positions (Figure 3.3b). Additional changes were observed when
the simulation was continued for an additional 5 ns in the AMBER simulation package.
By examining the changes in atomic interactions within each monomer, we can
determine how these conformational changes within the protease occur.
To compare the differences in conformation between monomers that occur during
the simulation it is easiest to focus on changes relative to a single residue. Ile15 in the
magenta loop is highlighted in Figure 3.5, which uses stereo images to illustrate the
changes in each monomer at 9 and 14 ns relative to the starting positions. In the
unliganded crystal structure Ile15 made van der Waal contacts with Leu33, Met36, and
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Leu38 in the red loop, and Ile62, Ile64, and Val75 in the cyan loop (Figure 3.5a). After 9
ns of molecular dynamics, however, this was no longer the case and the two monomers
adopt very different conformations. In one monomer, residues Leu33 and Leu38 in the
red loop slid over Ile15, increasing the contact between Leu38 and Ile15 (Figure 3.5b).
Simultaneously, the cyan loop slid downward as Ile15 exchanged contacts with Ile64 and
Val75 for contacts with Ile62 and Val77. The correlated movements between the residues
in the red and cyan loops, which are attached to either end of the flap region, facilitate the
movement of the flap region from the active site (Figure 3.3b). While correlated
movements of the red and cyan loops occurred in the second monomer, changes in the
red loop revolved around Ile13 instead of Ile15. In the second monomer residues Leu33
and Leu38 packed around Ile13, which left Ile15 partially solvated (Figure 3.5c). The
contacts that were made by Ile15 with the cyan loop were split between Ile13 and Ile15 in
this monomer. On one side of the cyan loop, Ile13 gained the contacts lost by Ile15 with
Val75. On the other side of this loop, Ile15 maintained contact with Ile62 and Ile64. In
this way, the red and cyan loops facilitated the movement of the flap region from the
active site over the first 9 ns.
Additional changes in both monomers were observed after continuing the
simulation for 5 ns in another force field. In the first monomer, the flap region appeared
to be moving back toward the active site. This change was facilitated by the upward
movement of the cyan loop as Val75 slid over Ile15 (Figure 3.5d). In the second
monomer, Ile15 moved back into the hydrophobic core displacing Ile13 as Leu38 slid
over Ile15 (Figure 3.5e). The red and cyan loops in this monomer moved together
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through the direct contact between Leu38 and Ile62, pulling the flap further from the
active site. The movements of these residues as they alter side chain conformations led to
correlated movements of the various loops in protease. These changes are likely to be
physically reasonable as they are primarily rearrangements of the hydrophobic residues
and there should be very little energetic penalty for exchanging one set of hydrophobic
van der Waal contacts for another.
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Figure 3.5
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Figure 3.5: Stereo images of the hydrophobic cluster during the MD1HHP simulation.
Residues 11-22 are colored magenta, 31-38 colored red, 39-57 colored blue, 58-78
colored cyan. 1-10, 22-24, 25-32, and 79-99 are colored grey.  a. Unliganded HIV-1
protease at the start of the simulation when both monomers are in the same conformation.
The same image is shown above both columns. b. Monomer A after 9 ns. c. Monomer B
after 9 ns. d. Monomer A after 14 ns. e. Monomer B after 14 ns.
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Discussion
HIV-1 protease undergoes a large conformational change in order for substrates
(or inhibitors) to access the active site. While the mechanism by which the flaps come
apart has been widely examined, in this study we have shown that an extensive
rearrangement of the core region may facilitate conformational changes in protease. This
rearrangement was not due to the exchange of inter-residue hydrogen bonds in the core.
As shown in figure 3.4, many hydrogen bonds were conserved between MD1HHP and the
less flexible simulations MDSUB and MDNOSUB. The backbone hydrogen bonds appeared to
stabilize the structure, while some of the side chain hydrogen bonds protected the
hydrophobic core from the solvent (Figure 3.4d). Further examination of the MD1HHP
simulation revealed that the mechanism of the observed conformational changes was the
exchange of van der Waal contacts within the hydrophobic core.
Nineteen residues from each monomer were found to comprise the hydrophobic
core. Seven of the nineteen residues in the core are isoleucines (Table 3.1), which have
more possible conformations than other hydrophobic residues such as phenylalanine. The
rotation of these isoleucines through various rotamers assists in the sliding of these
residues over one another. As demonstrated in Figures 3.3 and 3.5, the exchange of van
der Waal contacts between residues in the hydrophobic core is correlated with dynamic
changes in the protease structure. When any of the residues within this core region
mutate, they only mutate to other hydrophobic residues (Figure 3.1). This implies that
maintaining these hydrophobic contacts is important to the protease structure or function.
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Although a mutation likely would imply a change in dynamics. Based on these
observations, we propose that the conservation of hydrophobic residues is required for
the hydrophobic sliding that allows the conformational changes required for protease
function.
Of the 19 residues in the hydrophobic core, 6 are invariant (< 1% mutation rate)
among either treated or untreated patients (Table 3.1) (Shafer et al. 1999). Two of these
invariant residues, Leu5 and Leu97, are at the structurally conserved dimer interface, and
the sensitivity of these residues to mutation has already been shown (Loeb et al. 1989;
Choudhury et al. 2003). The other 4 invariant residues are Val11, Ala22, Leu38, and
Val75. Val11 and Ala22 do not interact with each other or with any of the other invariant
residues but are in constant contact with other highly variable residues in the hydrophobic
core. The remaining two invariant residues, Leu38 and Val75, are in separate loops in the
protease but they were in contact with each other throughout the simulation. However,
their positions relative to each other changed as the flap region slides down the side of
protease (Figures 3.3 and 3.5). The contact between Leu38 and Val75 may be a necessary
component of the flap movement as Leu38 slides over Val75 facilitating the relative
movement of the cyan and red loops. Facilitating this movement may explain why Leu38
and Val75 are invariant.
Many other residues in the hydrophobic core, however, are correlated with drug
resistance (Table 3.1) (Shafer et al. 1999; Johnson et al. 2004; Rhee et al. 2005). Two
residues within the hydrophobic core are considered primary sites for the development of
drug resistance, Leu33 and Leu90. Leu90Met is widely recognized as a primary mutation
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causing resistance to both saquinavir and nelfinavir and a secondary mutation to all other
inhibitors (Johnson et al. 2004). However, Leu33 is still conserved in 98% of the
untreated and 94% of the treated patient population (Table 3.1). The development of
mutations at this site, particularly Leu33Phe, appears to be related to the most recent
generation of protease inhibitors. Leu33 is packed into the core of each monomer
throughout the simulation and interacts with many different residues (Figure 3..5).
Mutation to phenylalanine would alter the packing of the core as the other residues
shifted to accommodate the larger sidechain. Additionally, phenylalanine has different
properties than leucine. The aromatic ring, while non-polar, is capable of forming
hydrogen bonds. Therefore, this change would likely affect the conformational flexibility
of the monomer both by altering the packing of the core and by potentially forming
hydrogen bonds with backbone atoms. Interestingly, in sequences with Leu33Phe
mutations the frequency of mutation for other residues within the hydrophobic core
increases. These changes include increases relative to the general population of Ile13Val
from 34% to 51%, Ile62Val from 16% to 48%, and Val77Ile from 18% to 35%. While
each of these mutations is correlated with drug resistance, their role has not previously
been uncovered. However, the interactions of these residues with each other in the
hydrophobic core may explain the interdependence of these mutations. Based on the
cooperativity of their movements and their mutational frequencies, we hypothesize that
the role of these sites in drug resistance is to modify the conformational flexibility of
HIV-1 protease. The interaction between protease and its substrate is a highly dynamic
process. Protease undergoes a large conformational change to bind its substrate, cleave a
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peptide bond, and then release the protein product. However, ideally the binding of
inhibitors to the protease should be less dynamic because the inhibitor should stay bound
to the protease for a longer period of time then the substrate. Mutations that increase the
flexibility of HIV-1 protease may detrimentally impact inhibitor binding by increasing
the rate of dissociation between the protease and the inhibitor. Additionally, mutations
that alter the conformational flexibility of the protease may affect the transition state
between unliganded and liganded protease, thereby specifically detrimentally impacting
the recognition of inhibitor over substrates.
This study has demonstrated the correlated motion of 19 hydrophobic residues
within the hydrophobic core. This extensive rearrangement of a hydrophobic core to
allow a conformational change has not been previously elucidated and is not easily
observed experimentally. However, such a change could occur with minimal energetic
expense for the protein because the overall packing remains intact and the changes only
involve the exchange of hydrophobic interactions. Mutation at sites within the core to
other hydrophobic residues could affect the conformational range of the protease and,
therefore, the ease by which the inhibitors or substrates can bind. This could explain the
role of these residues in either causing or contributing to drug resistance. However, in
order to fully understand their role of these residues in drug resistance, we must further
examine their role in the dynamic conformational changes in HIV-1 protease.
More generally, the mechanism of hydrophobic sliding probably represents a
common mechanism by which protein undergo conformational changes. Most proteins
have either hydrophobic cores or hydrophobic surfaces, which are often invoked in the
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understanding of protein folding. These hydrophobic regions likely also facilitate
dramatic conformational changes, at a minimal energetic expense, that are necessary for
the protein function.
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CHAPTER IV
COOPERATIVE EFFECTS OF DRUG RESISTANCE MUTATIONS IN THE FLAP
REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE
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Abstract
Despite significant research efforts and global public awareness campaigns, HIV
continues to be one of the greatest public health challenges of our time. Nine FDA approved
inhibitors for the viral protease exist, yet the virus has adapted to evade each. One of the most
essential regions of HIV protease is the flap region, which consists of many residues that
mutate only under the pressure of inhibitor therapy. In the flap, Ile54, which is significantly
correlated with the development of drug resistance, frequently mutates to valine and, more
recently, alanine. A series of patient sequences containing the mutation Ile54Ala were
evaluated for the most frequently occurring co-mutations. Ile54Ala was found to occur with
mutations that were previously correlated with Ile54Val mutations, including Leu10Ile,
Gly48Val, and Val82Ala. Based on the results of this evaluation, the binding properties of
five variant proteases were investigated: MDI54V, MDRI54A, I54V, I54A, and G48V. MDRI54V
and MDRI54A each contained the mutations Leu10Ile, Gly48Val, and Val82Ala, and either
Ile54Val or Ile54Ala, respectively. The other variants contained only the mutation indicated.
Isothermal titration calorimetry was used to examine the binding thermodynamics between
the variants and saquinavir, amprenavir, and the recently approved darunavir. Mutations at
Ile54 were able to significantly impact the thermodynamics of binding to all inhibitors. The
magnitude of this impact depended on the presence or absence of other drug resistance
mutations, including another mutation in the flap region, Gly48Val. Therefore, while residues
48 and 54 are not in contact with each other, mutations at both sites have a cooperative effect
that varies between inhibitors.
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Introduction
Human Immunodeficiency Virus (HIV) protease is one of the primary targets in
the development of new treatments for HIV infection. It is a homodimeric aspartyl
protease consisting of 99 amino acids in each monomer. It is also highly polymorphic.
All but 27 of its 99 residues have been shown to vary either naturally or in response the
selective protease inhibitor (PI) therapy(Shafer et al. 1999). Despite an abundance of
patient sequence, structural, and biochemical information on HIV protease, the
mechanism by which many mutations cause drug resistance is still unclear.
When the protease binds substrates, the flap region in each monomer encases the
substrate in the active site (Prabu-Jeyabalan et al. 2000; Prabu-Jeyabalan et al. 2002).
Both flaps are necessary for substrate binding. This region of HIV-1 protease has been
the site of extensive studies of sequence tolerance (Shao et al. 1997) and of the
mechanism by which the flap region separates to allow substrates access to the active site
(Collins et al. 1995; Collins et al. 1995; Ishima et al. 1999; Scott et al. 2000; Perryman et
al. 2004; Meagher et al. 2005; Hornak et al. 2006; Perryman et al. 2006; Toth et al.
2006). Mutations in the flap region of protease are among the most common treatment-
associated protease mutations (Young et al. 1998; D'Aquila et al. 2002; D'Aquila et al.
2003; Johnson et al. 2003; Johnson et al. 2004; Johnson et al. 2005) (Figure 4.1). One
residue, Ile54, is of particular interest because at least six different treatment associated
substitutions occur at this otherwise nonpolymorphic position (Paulsen et al. 2002;
Johnson et al. 2005; Svicher et al. 2005). However, despite significant evidence of its
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involvement in drug resistance, little is known about the impact of mutations at residue
54 on inhibitor binding. We chose to study one particular mutation at this position,
Ile54Ala, because alanine is very different from the native isoleucine as well as from the
most commonly occurring mutations at this position (valine, methionine, and leucine). In
addition, a mutation from isoleucine to alanine, requires two nucleotide changes,
suggesting that viruses with this mutation must have a strong selective advantage in the
presence of certain drugs for the improbable mutation to develop.
In this study a series of patient sequences containing Ile54Ala mutations were
studied for the most frequently occurring co-mutations. This information confirmed that
Ile54Ala mutations commonly occur with the same mutations as Ile54Val. Therefore,
four new variant proteases were generated. One protease variant contained the mutations
Leu10Ile, Gly48Val, Ile54Ala, and Val82Ala. The other three variants contained either
Ile54Val, Ile54Ala, or Gly48Val. These variants were studied for changes in binding to
the protease inhibitors saquinavir (SQV), amprenavir (APV), and darunavir (DRV). The
results indicate that residues in the flap region have complex cooperative effects on drug
resistance that can vary between inhibitors.
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Figure 4.1
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Figure 4.1: HIV-1 protease colored by sequence conservation (Shafer et al. 2001).
Residues colored red are invariant in both untreated and treated populations of patients.
Those colored yellow are invariant only in the untreated population. Invariant glycine
residues are colored blue. a. The unliganded protease structure, 1HHP. The side chains of
the catalytic aspartic acids, Asp25, as well as Leu10, Ile54, and Val82 are displayed. b. A
liganded protease structure with the catalytic aspartic acids, Asp25, Ile10, Val48, Val54,
and Ala82 displayed.
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Materials and Methods
Patient Sequences. Patient sequences were obtained from patients who had
plasma samples submitted for genotypic resistance testing at Stanford University Hospital
between July 1997 and June 2006. Genotypic resistance testing of these samples was
performed using a previously described sequencing protocol (Shafer et al. 2001). Briefly,
RNA was extracted from 0.2 ml - 0.5 ml of plasma using a guanidine thiocyanate lysis
reagent. Reverse-strand cDNA was generated from viral RNA, and first-round PCR was
performed using Superscript One-Step RT-PCR (Life Technologies, Rockville, MD).
Nested PCR was used to amplify a 1.3-kb product encompassing the protease gene and
the first 300 residues of the RT gene. Direct PCR cycle sequencing was performed with
AmpliTaq DNA FS polymerase and dRhodamine terminators (Applied Biosystems Inc.,
Foster City, CA).
Protease Gene Construction. The synthetic gene for the wild type HIV-1 protease
sequence was made using codons optimized for protein expression in Escherichia coli,
and included a substitution of Gln7Lys to prevent autoproteolysis (Rose et al. 1993).
Mutagenesis was performed with the Stratagene® Quikchange™ Site Directed
Mutagenesis Kit, and confirmed by sequencing to generate 4 new plasmids. All plasmids,
including WT, contained the polymorphism Leu63Pro. One plasmid contained Leu10Ile,
Gly48Val, Ile54Ala, and Val82Ala. The three other plasmids contained either Gly48Val,
Ile54Val, or Ile54Ala.
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Protease expression and purification. The expression and purification of HIV-1
protease was previously described (King et al. 2004; Prabu-Jeyabalan et al. 2004).
Briefly, the HIV protease gene was cloned into the plasmid pXC-35 (ATCC) (Cheng et
al. 1992), which was transfected into Escherichia coli TAP56. Transfected cells were
grown in a 12 L fermenter and, following protein expression, lysed to release the
inclusion bodies containing the protease (Hui et al. 1993). Inclusion bodies were isolated
by centrifugation and the pellet was dissolved in 50% acetic acid to extract protease.
High molecular weight proteins were separated from the desired protease by size
exclusion chromatography on a 2.1 L Sephadex G-75 superfine (Sigma Chemical)
column equilibrated with 50% acetic acid. Refolding was accomplished by rapidly
diluting the protease solution into a 100-fold excess of refolding buffer. Excess acetic
acid was removed through dialysis.
Isothermal Titration Calorimetry. To assess changes in the interaction between
each protease variant and the inhibitors APV and DRV, the binding affinity and enthalpy
of interaction between each protease variant and inhibitor were measured using
competitive displacement ITC experiments (Sigurskjold 2000; Todd et al. 2000;
Valzaquez-Campoy et al. 2001; Ohtaka et al. 2002) on a VP- isothermal titration
calorimeter (MicroCal Inc., Northampton, MA). These experiments were performed as
previously described (King et al. 2004; Foulkes et al. 2006). The buffer used for all
protease and inhibitor solutions consisted of 10 mM sodium acetate (pH 5.0), 2.0%
148
dimethyl sulfoxide, and 2 mM Tris (2-carboxyethyl) phosphine. Depending on the variant
and inhibitor being used, protease concentrations were between 12 and 45 µM, as
determined by the absorbance of the solution at 280 nm. The protease solution was first
saturated with 0.3 to 0.4 mM pepstatin. Pepstatin was then displaced from protease by
titrating 0.066 – 0.2 mM DRV or APV into the protease/pepstatin solution. Heats of
dilution were subtracted from the corresponding heats of reaction to obtain the heat due
solely to the binding of ligand to enzyme. The binding affinity and enthalpy of the
interaction between the protease and APV or DRV were obtained by using the Origin7
software to subtract the enthalpy and binding affinity of pepstatin from the final
displacement reaction. Direct titration experiments of SQV were performed for all
variants because the direct titration of SQV versus these variants yielded high-quality
results. 7 – 10 µL aliquots of 0.2 mM SQV were injected into solutions containing 20 –
40 µM protease. Data were processed and analyzed using the MicroCal Origin7 software
package. Final results represent the average of at least three measurements.
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Results
Cooperative effects of protease mutations in the flap region were examined in six
protease variants: WT, MDRI54V, MDRI54A, I54V, I54A, and G48V. I54V, I54A, and
G48V contained only a single mutation. MDRI54V and MDRI54A each contained the
mutations Leu10Ile, Gly48Val, Val82Ala, and either Ile54Val or Ile54Ala.
Common mutations occurring with Ile54Ala in the patient population. From 1997
to 2006, protease genes from 8,060 plasma virus isolates from 5,174 people were
sequenced. One or more PI-resistance mutation was present in 43.0% (3,463) of viruses;
and viruses with PI-resistance mutations were present in 39.0% (2,018) of people.
Antiretroviral treatment histories, plasma HIV-1 RNA levels, and CD4 lymphocyte
counts were available on each of the 13 patients in whom Ile54Ala occurred. Table 4.1
summarizes the PI’s received by the patients with Ile54Ala and the mutations that co-
occurred with Ile54Ala.
All 13 patients with Ile54Ala had previously received the PI indinavir; 8 received
ritonavir usually in combination with another PI, 4 received saquinavir, 4 received
nelfinavir, and 1 received lopinavir. For seven patients in whom the development of I54A
could be localized to a specific PI, six were receiving either indinavir or
indinavir/ritonavir. In six of eight patients with more than one sequence, Ile54Val
preceded Ile54Ala. In four patients, in whom a repeat sequence was available while on a
PI containing regimen, all four had viruses with Ile54Ala. One of these two converted
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from alanine at residue 54 to valine in a subsequent time point. The remaining 6 had
Ile54Val in their first time point sequence and subsequently converted to alanine, which
suggests, as expected, that mutation to alanine at residue 54 frequently happens after
mutation to valine.
Among the thirteen patients there were noticeable patterns of mutations. While
there were 36 total sequences from multiple time points, only 20 sequences contained
Ile54Ala. These 20 sequences also contained Leu10Ile in 15 of the sequences, Gly48Val
in 8 of the sequences, and Val82Ala in 9 of the sequences. The other most frequently
observed drug resistance mutations were Ala71Val (15), Val82Thr (9), Leu90Met (9),
Met46Ile (6), and Lys20Arg (5). Within the five patients who started with Ile54Val there
were 14 sequences. The most frequent drug resistance mutations occurring in these 5
patients with Ile54Val before they converted to alanine were Leu10Ile (4), Val82Ala (3),
Gly48Val (3), Ala71Val (3), Val82Thr (3), Ala71Thr (2), and Leu90Met (2). These
sequences confirm that mutations at residue 54 to alanine happen with similar mutations
as when residue 54 mutates to valine. This information also demonstrated that protease
variants with Leu10Ile, Gly48Val, and Val82Ala, in combination with Ile54Val or
Ile54Ala existed in the patient population and were a reasonable model for studying
cooperativity of flap mutations.
 Thermodynamic parameters of inhibitor binding. To determine the impact of
these mutations on inhibitor binding, isothermal titration calorimetry (ITC) was used to
measure the binding affinity and thermodynamic parameters of each variant versus three
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inhibitors: saquinavir (SQV), amprenavir (APV), and darunavir (DRV). SQV was chosen
for this study because Gly48Val and Val82Ala are both related to SQV resistance
(Johnson et al. 2005). APV and DRV were used because in a recent study with six
different protease inhibitors, MDRI54V was found to dramatically alter the enthalpy and
entropy of binding while maintaining approximately the binding affinity (King, et al.
Manuscript in preparation). Therefore, we were interested in the response of MDRI54A and
each of the single variants to these two inhibitors. The results are presented in Table 4.2.
Relative to each other, each of the single mutation variants, G48V, I54V, and I54A,
behaved similarly (Figure 4.2). Like WT, all variants had binding to SQV that was
enthalpically unfavorable and entropically favorable, and binding to APV and DRV that
was both enthalpically and entropically favorable. While the general trend was the same,
each mutation did have varying effects on the thermodynamic parameters of binding for
these inhibitors. For example, both I54V and G48V had a 3 kcal mol-1 less favorable
enthalpy of binding to SQV, relative to WT, while I54A had a 4 kcal mol-1 less favorable
enthalpy of binding . Each variant had a more favorable entropy of binding to SQV than
WT, but the magnitude of this change was different. I54V had a 3 kcal mol-1 more
favorable entropy of binding, I54A had a 2 kcal mol-1 more favorable entropy of binding,
and G48V had a 1.2 kcal mol-1 more favorable entropy of binding to SQV (Table 4.2).
The end result of these varying changes in enthalpy and entropy of binding to SQV was
that the binding free energy of I54V relative to WT did not change, but there was a 2 kcal
mol-1 decrease in the free energy of binding between SQV and I54A or G48V. While
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each mutation affected the thermodynamic parameters of binding to SQV differently,
their effects also varied between inhibitors.
While the G48V and I54A variants bound SQV with a similar free energy, I54V
and I54A bound DRV with almost the same free energy, –14.8 and –14.7 kcal mol-1,
respectively, despite differences in the enthalpy and entropy of binding with this
inhibitor. Relative to I54A, the enthalpy of binding between DRV and I54V was 2 kcal
mol-1 less favorable and the entropy of binding was 2 kcal mol-1 more favorable. In
contrast, relative to I54A, the binding of G48V to DRV was both 1 kcal mol-1 less
enthalpically and entropically favorable. Each individual mutation had a unique impact
on HIV protease, and these changes affected the binding of each inhibitor differently.
Additionally, when combined together in MDRI54V and MDRI54A they caused more
significant differences in the thermodynamic parameters of binding relative to WT.
A comparison of G48V, I54V, MDRI54V versus SQV, APV, and DRV revealed
that the combined effect of these mutations on HIV protease was greater than the sum of
the changes induced by the individual mutations. While the binding of both G48V and
I54V to both APV and DRV was enthalpically favorable, the binding of MDRI54V to
either inhibitor was enthalpically unfavorable (Figure 4.2). Furthermore, the binding
between both G48V and I54V and both APV and DRV had a more favorable enthalpy
than entropy, implying that these interactions were driven more by the enthalpic
component of free energy. Conversely, the interaction between MDRI54V and either APV
or DRV was driven by the entropic component of free energy (Figure 4.2). The
differences between the reactions of G48V, I54V, and MDRI54V are illustrated in Figure
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4.3, which shows the changes in each thermodynamic parameter relative to WT. G48V
and I54V altered the enthalpy and entropy of binding to APV by less than 1 kcal mol-1.
However, the enthalpy and entropy of binding between MDRI54V and APV changed by 11
and 10 kcal mol-1, respectively. Similar differences between the single mutant variants
compared with MDI54V were observed for the binding between DRV and G48V, I54V, or
MDRI54V (Figure 4.3). Once again, MDRI54V had a more significant change in the
enthalpy and entropy relative to WT than the sum the changes observed for G48V or
I54V. Relative to either G48V or I54V, MDRI54V did have the additional active site
mutation Val82Ala. However, these dramatic changes in the enthalpy and entropy of
binding between MDRI54V were not likely due to this mutation because less dramatic
changes were not observed for the binding of MDRI54A to these inhibitors.
While there were only small differences between the free energy of binding of
MDRI54V and MDRI54A for any inhibitor, there were considerable differences in the
enthalpy and entropy of binding. For instance, the free energy of binding between
MDRI54V and APV and between MDRI54A and APV differed by only 0.2 kcal mol-1.
However, when binding APV, the enthalpy of binding was 10 kcal mol-1 less favorable
for MDRI54V versus MDRI54A and the entropy of binding was 10 kcal mol-1 more favorable
(Table 4.2). Similar to APV, the difference in free energy between MDRI54V and MDRI54A
when binding DRV was only 0.6 kcal mol-1. However, the enthalpy of binding between
MDRI54V and DRV was 9 kcal mol-1 less favorable and the entropy of binding was 9 kcal
mol-1 more favorable than between MDRI54A and DRV. These changes not only affected
the magnitude of the enthalpy and entropy of binding, but also the ratio of their
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contribution to the free energy of binding. As mentioned previously, the binding of
MDRI54V to both APV and DRV was enthalpically unfavorable and these reactions were
entirely driven by the entropy of binding (Figure 4.2). In contrast, the enthalpic and
entropic components of binding contributed equally to the free energy of binding between
MDRI54A and APV or DRV. The differences between MDRI54V and MDRI54A clearly
indicated that changes at Ile54 could alter the binding of inhibitors. However, when
compared with the differences between I54V and I54A it was apparent that mutations at
Ile54 have a greater impact when combined with other mutations.
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Table 4.1
Patient
Number
Protease Inhibitors Received
Preceding Mutation
Prior amino
acid at 54
Protease Mutations Present in First
Isolate with I54A
795 SQV, NFV, IDV, IDV/RTV I54V L10I, I15V, M36I, G48V, I54A,
I62V, I64V, V82A
1144 RTV/SQV, NFV, IDV/RTV I54V L10V, T12KT, L19I, M46L, G48V,
F53Y, I54A, Q58E, Q61E, I62V,
L63P, A71V, I72V, T74S, V77I,
V82TA, L90M, I93L
1415 IDV, NFV Unknown L10I, E34Q, K43T, I54A, L63P,
A71V, V82A, Q92K
1595 IDV, RTV/SQV I54V L10I, I13V, L19V, K20R, E35D,
M36I, N37D, I54A, I62V, L63P,
I66F, A71I, V82T
3871 SQV, IDV Unknown L10I, I13V, K14R, I15V, K20M,
M36V, N37T, I54A, I62V, I64V,
A71V, V82F, L89I
5015 IDV, IDV/RTV I54V L10I, I13AV, K20I, E35D, M36I,
N37D, M46IM, I54AV, R57K,
L63P, I64VI, I66F, A71V, I72LI,
V82T, L90ML
6406 RTV, NFV, IDV/NFV Unknown L10I, K43T, G48V, I54A, I62V,
L63P, I64V, V77I, V82A, L90M
7950 NFV, IDV/RTV I54V L10F, V11IV, I13V, K20RK,
D30N, L33I, E35D, M36I, N37C,
I54A, I62V, L63P, A71T, N88D,
I93L
14302 IDV WT L10I, I54A, I62V, L63P, A71V,
V82A
14612  Unknown PI, IDV/RTV Unknown L10I, L19I, K20R, E35D, M36I,
N37D, I54A, I62V, L63P, C67F,
H69R, A71I, I72M, G73S, V82I,
L90M
22055 IDV, LPV/RTV Unknown L10I, N37D, M46I, I54A, D60E,
I62V, L63P, I64V, A71V, I72R,
V82A
22166 IDV WT T12S, L19I, K43R, M46I, I54A,
Q58E, L63P, A71V, V77I, V82A,
I93L
27937 IDV WT L10I, N37DN, M46I, I54A, D60E,
Q61G, I62V, L63T, I66L, A71V,
I72R, V77I, V82A, I93L
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Table 4.1: Treatment history and sequences information for patients in this study.
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Table 4.2
Variant Ka (M-1) Kd (nM)
Kd
Ratio
∆H
kcal mol-1
-T∆S
kcal mol-1
∆G
kcal mol-1
SQV
wild typea (2.0 ± 0.1) × 109 0.50 ± 0.03 3.6 ± 0.1 –16.1 ± 0.1 –12.5 ± 0.1
MDRI54V
c (5.7 ± 0.1) × 106 170 ± 4 350 12.9 ± 0.1 –21.9 ± 0.1 –9.1 ± 0.1
I54V (1.1 ± 0.6) × 109 0.93 ± 0.6 1.9 7.0 ± 0.2 –19.1 ± 0.4 –12.1 ± 0.3
MDRI54A (1.1 ± 0.1) × 106 880 ± 40 1800 10.7 ± 0.3 –18.8 ± 0.3 –8.1 ± 0.1
I54A (4.3 ± 0.3) × 107 23 ± 2 47 8.0 ± 0.1 –18.2 ± 0.1 –10.2 ± 0.1
G48V (5.8 ± 0.3) × 107 17 ± 1 34 6.9 ± 0.1 –17.3 ± 0.1 –10.4 ± 0.1
APV
wild typeb (2.6 ± 1.3) × 109 0.39 ± 0.20 -7.3 ± 0.9 –5.3 ± 0.9 –12.6 ± 0.3
MDRI54V
c (7.6 ± 0.1) × 108    1.31 ± 0.01 3.3 3.3 ± 0.5 –15.2 ± 0.5 –11.9 ± 0.1
I54V (7.4 ± 0.4) × 109  0.14 ± 0.01 0.3 -7.2 ± 0.5 –6.0 ± 0.5 –13.2 ± 0.1
MDRI54A (1.0 ± 0.1) × 109  0.99 ± 0.09 2.5 -7.0 ± 0.8 –5.1 ± 0.8 –12.1 ± 0.1
I54A (1.5 ± 0.1) × 109 0.66 ± 0.04 1.7 -7.3 ± 0.2 –5.0 ± 0.2 –12.3 ± 0.1
G48V (2.9 ± 0.3) × 109 0.34 ± 0.03 0.9 -7.4 ± 0.5 –5.3 ± 0.5 –12.7 ± 0.1
DRV
wild typeb (2.2 ± 1.1) × 1011 0.0045 ± 0.002 -12.1 ± 0.9 –3.1 ± 0.9 –15.2 ± 0.3
MDRI54V
c (3.9 ± 0.7) × 1010 0.026 ± 0.005 5.7 2.0 ± 0.6 –16.2 ± 0.6 –14.2 ± 0.1
I54V (1.2 ± 0.3) × 1011 0.0083 ± 0.002 1.9 -8.9 ± 0.3 –5.9 ± 0.4 –14.8 ± 0.1
MDRI54A (1.4 ± 0.2) × 1010 0.074 ± 0.01 16 -7.0 ± 0.4 –6.6 ± 0.4 –13.6 ± 0.1
I54A (9.5 ± 0.1) × 1010 0.011 ± 0.001 2.3 -10.6 ± 0.1 –4.1 ± 0.1 –14.7 ± 0.1
G48V (1.4 ± 0.1) × 1010 0.073 ± 0.004 16 -10.3 ± 1.6 –3.3 ± 1.6 –13.6 ± 0.1
a. (Foulkes et al. 2006)
b. (King et al. 2002)
c. (King et al. 2006)
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Table 4.2: Thermodynamic parameters of binding for each variant versus SQV, APV, and
DRV at 20 ºC.
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Figure 4.2
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Figure 4.2: Thermodynamic parameters of binding for each variant versus APV, DRV,
and SQV. The free energy of binding (∆G) is the unfilled bars, the enthalpy of binding
(∆H) is the dotted bars, and the entropy of binding (T∆S) in the lined bars.
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Figure 4.3
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Figure 4.3: Changes in the thermodynamic parameters of binding relative to wild type
protease. The free energy of binding (∆G) is the unfilled bars, the enthalpy of binding
(∆H) is the dotted bars, and the entropy of binding (T∆S) in the lined bars.
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Discussion
Despite more than 20 years of scientific research and the development of
numerous inhibitors, HIV protease adapts to evade each new inhibitor while still
maintaining enzymatic function. In order to develop the most effective pharmaceutical
agents, we must first develop a better understanding of the mechanism of drug resistance.
An examination of protease sequences containing Ile54Val or Ile54Ala mutations
revealed that these mutations often occur in a stepwise fashion and with similar co-
mutations. One of the most frequently observed co-mutations was Gly48Val, which is
also in the flap region. While Ile54 does not contact either substrates or inhibitors (Figure
4.1), mutations at both Gly48 and Ile54 have been well correlated with drug resistance to
multiple inhibitors (Baldwin et al. 1995; Paulsen et al. 2002; Shuman et al. 2003; Johnson
et al. 2005). This study explores the impact of these mutations on inhibitor binding both
individually and combined with other frequently observed mutations.
In a population of more than 4000 patients infected with HIV, 13 patients had the
Ile54Ala mutation in their viral protease. These patients had been on various therapies,
and had a number of other protease drug resistance mutations. Nonetheless, we were able
to determine a pattern of mutations that frequently occur with Ile54Ala. These mutations
were found to be the same as those that frequently occur with the mutations Ile54Val. In
order to confirm these results in a slightly larger patient population, we examined the
Stanford Database (Shafer et al. 1999) for other patient sequences that contained
Ile54Ala. After the removal of sequences in the database that were already discussed in
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this study, there were 30 sequences from 24 patients (four patients had data from more
than one time point). The patterns found confirmed the results from the smaller patient
sampling. Of the mutations investigated in this study, Leu10Ile occurred in 87% of
sequences, Gly48Val in 33%, and Val82Ala in 70%. Other drug resistance mutations that
occurred more than 50% of the time included Met36Ile (53%) and Ala71Val (63%).
Though the 13 patients specifically sequenced at Stanford University were all from
subtype B, the 24 patients other patients in the Stanford Database included 8 sequences
from other subtypes including C, CRF01_AE, F, and G. This demonstrates that similar
patterns exist even among other subtypes. Therefore, the variants examined in this study
are clinically relevant to a broad patient population.
Each of the single mutations, Gly48Val, Ile54Val, or Ile54Ala, altered the
thermodynamic parameters of binding for one or more of the inhibitors examined. When
these results are compared with those of MDRI54V or MDRI54A, the changes induced by
individual mutations at Gly48 and Ile54 showed the effects of the mutations were not
additive. For example, when I54A binds DRV, the changes in enthalpy, entropy, and free
energy of binding relative to WT were 1, –1, and 0.5 kcal mol-1, respectively. When
G48V binds DRV, the changes in enthalpy, entropy, and free energy of binding were 2,
–0.2, and 1.6 kcal mol-1, respectively. However, the changes in enthalpy, entropy, and
free energy of binding when MDRI54A binds DRV were 5, –3.5, and 1.6 kcal mol-1,
respectively, which is significantly different than if the changes induced by G48V and
I54A were simply additive. Similarly, the changes in the binding thermodynamics
observed in MDRI54V were not simply the sum of the changes observed in G48V and
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I54V relative to WT (Table 4.2). These cooperative interdependent effects of mutations
were observed throughout this study though they varied between inhibitors.
This kind of cooperativity between residues that are not in contact with each other
has been previously illustrated (Muzammil et al. 2003; Ohtaka et al. 2003). However, the
origins of this effect have yet to be elucidated. While not in contact with each other, both
Gly48 and Ile54 are in the flap region of protease (Figure 4.2) and could exert their
effects by altering the dynamic movements of this region that allow substrates to access
the active site. Gly48 is at the flap tip of protease, which is the most dynamic region of
the unliganded protease (Nicholson et al. 1995; Ishima et al. 1999; Scott et al. 2000;
Freedberg et al. 2002). A mutation from glycine to valine would significantly restrict the
backbone flexibility at this site, thereby altering the conformational range of the tip of the
flap. On the opposite side of the flap from Gly48 is Ile54. In crystal structures of the
bound protease, Ile54 is in contact with Ile50 of the other monomer (Figure 4.4).
However, in the unbound protease, Ile54 interacts with residues in the P1-loop including
Pro79 and the backbone of Thr80 (Figure 4.1). These interactions may be important for
stabilizing the flap region. Mutation of Ile54 to valine or alanine would decrease the
contact between Ile54 and the P1-loop possibly increasing the conformational flexibility
of protease. Consequently, while the Gly48Val mutation may limit the flexibility of the
flap region, Ile54Val and Ile54Ala may increase the flexibility. Therefore the observed
cooperativity of these mutations is likely due to their effects on flap dynamics.
Mutations that alter the conformational flexibility of protease can affect the
entropy of binding between protease and its ligand. Changes in binding affinity occur
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when changes in the entropy of binding between protease and inhibitor are not
compensated by changes in the enthalpy of binding. The Ile54Val mutation led to the best
enthalpy and entropy compensation as both I54V and MDRI54V had significant changes
in the enthalpy and entropy of binding that did not cause such substantial changes in the
binding affinity (Figure 4.3). Not all mutations at Ile54 affect the enthalpy and entropy
compensation uniformly. Ile54Ala mutations did not cause as significant changes in the
enthalpy and entropy of binding as Ile54Val mutations, but this mutation did not lead to
the same levels of compensation observed for Ile54Val mutations. Therefore the binding
affinity of I54A and MDRI54A versus either SQV or DRV decreased significantly more
than I54V and MDRI54V, respectively. This implies that drug resistance develops when
mutations alter the balance between the entropy and enthalpy of protease binding to
inhibitors. Conversely, inhibitors are most effective when they are not influenced by the
enthalpy and entropy changes in the protein caused by mutation. With the exception of
MDRI54V, none of the variants dramatically affected the enthalpy or entropy of binding to
APV. Even though the enthalpy and entropy changes between MDRI54V and APV
compensated each other, there was something specific about the combination of
mutations in MDRI54V that disturbed the enthalpy and entropy of binding to APV.
However, because the other variants did not affect the enthalpy and entropy of binding to
APV as they did to DRV and SQV, APV was not influenced by the same changes in
protease that led to the enthalpy and entropy changes observed for the other inhibitors.
This implies that APV interacts differently with the flap region than DRV and SQV.
167
Understanding the role of drug resistant mutations in the development of drug
resistance is crucial to the development of new inhibitors. As protease continues to adapt
to evade inhibitors while still maintaining the ability to specifically recognize and
efficiently cleave its substrates, the problem of drug resistance has become more
complicated by the interdependence of multiple drug resistant mutations. While previous
studies have shown that the development of mutations at Gly48 and Ile54 are correlated
(Sevin et al. 2000; Hoffman et al. 2003; Wu et al. 2003; Svicher et al. 2005), this study
provides some insight into the reason for this correlation. A series of protease variants
containing mutations in the flap region of protease, specifically Gly48Val, Ile54Val, and
Ile54Ala, had cooperative effects that altered the thermodynamic parameters of binding.
The end result in most cases was a decrease in binding affinity for protease inhibitors that
is likely due to the impact of these mutations on flap dynamics.
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Figure 4.4
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Figure 4.4: Relative positions of mutated residues to inhibitors. HIV-1 protease is bound
to SQV. Ile10, Gly48, Ile54, and Val82 are displayed in cyan with van der Waal spheres.
The SQV molecule is also displayed with van der Waal sphere and colored according to
atom type, where grey is carbon, blue nitrogen, and red oxygen. a. The front view
illustrates that neither residue 10 nor residue 54 are in contact with the inhibitor. b. The
top view shows that residue 54 is in close contact with Ile50 of the other monomer.
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CHAPTER V
CONCLUSION
181
The results of this study address two of the fundamental questions of protein biology:
how proteins undergo conformational changes to bind a ligand and how mutations
outside the active site of proteins cause changes in ligand binding. Through a
combination of biophysical methods, such as Molecular Dynamics (MD) simulations and
Isothermal Titration Calorimetry (ITC) , we gain information about the dynamic
properties of proteins. These methods were used to study wild type and variant HIV-1
proteases with mutations outside the active site. The MD simulations demonstrate that
non-active site residues have a role in the dynamic properties of protease. The results of
the ITC experiments illustrate that mutations at these residues can dramatically affect the
thermodynamic properties of binding to inhibitors. This study also demonstrates that
differences in entropy of binding can be correlated with changes in the dynamic
properties of the system. Therefore, we can infer information about protein dynamics
from the ITC results. Because ligand binding and release is a dynamic process, mutations
that modify the dynamic properties of protease could alter the ability of protease to bind
inhibitors and substrates. Mutations that preferentially affect inhibitor binding over
substrate binding would then lead to drug resistance. As indicated by the results of this
study, residues outside the active site are important for protein dynamics. Therefore, we
propose that mutations at these residues cause drug resistance by altering the dynamic
properties of protease and altering the balance between substrate and inhibitor binding.
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Thermodynamics and Protein Dynamics
Through the use of Isothermal Titration Calorimetry (ITC), this work clearly
demonstrates that mutations outside the active site affect the binding thermodynamics of
protease inhibitors. Chapter II shows that a single mutation at Thr80, which does not
usually contact substrates or inhibitors, caused remarkable differences in the enthalpy and
entropy of binding (Table 2.2). Relative to WT, the enthalpy of binding between T80N
and SQV was 18 kcal mol-1 less favorable and the entropy of binding was 13 kcal mol-1
more favorable. As shown in chapter IV, these differences in the enthalpy and entropy of
binding were not unique to this protease variant (Table 4.2 and Figure 4.4). The
combination of multiple mutations, including G48V and I54V/A in the flap region,
caused dramatic changes in the enthalpy and entropy of binding between HIV-1 protease
and several inhibitors. For example, MDRI54A had a 7.0 kcal mol-1 less favorable enthalpy
of binding and a 2.7 kcal mol-1 more favorable entropy of binding versus SQV than WT.
These dramatic changes in the thermodynamics of binding between protease variants
indicate that mutations outside the active site are altering a property of the protease, such
as the conformational flexibility.
The enthalpy and entropy of binding are intrinsically tied to structural and
dynamic properties of the system. While enthalpy of binding is related to inter-atom
contacts, the entropy is related to the degree of disorder, i.e. dynamic properties, of the
system. This correlation between entropy and the dynamic properties of a system was
illustrated in Chapter II when a single mutation outside the flap region altered flap
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dynamics. Thr80, a residue in the P1-loop, was mutated to a series of different amino
acids, including asparagine. In MD simulations, T80N prevented the flap region from
uncurling into the solvent because the side chain oxygen of Asn80 formed a stable
hydrogen bond with the backbone nitrogen of Gly49 (Figure 2.7). These results provided
a possible explanation for the experimental findings. This variant was determined to be
catalytically inefficient for cleaving a substrate analogue and in viral culture (Figure 2.3).
This correlates with a dramatic difference in the entropy of binding between T80N and
SQV relative to WT (Table 2.2). Static protein crystal structures of T80N bound to SQV
reflected significant structural homology between the enzymatically inactive T80N and
the enzymatically active T80S. However, using MD simulations to examine the dynamic
properties of protease, the loss of function could be correlated with a loss conformational
flexibility. Therefore, these large changes in enthalpy and entropy for protease variants
with mutations that are not in contact with substrates or inhibitors could indicate
significant changes in the dynamic properties of the protease.
In order to examine the dynamic properties of a single protease molecule, MD
simulations were performed for a variety of protease variants. While the flap region is the
most dynamic region in protease, MD simulations suggest a role for other areas of the
protease in protein dynamics. In chapter III, hydrophobic residues in the core of each
monomer of HIV-1 protease were shown to facilitate a dramatic conformational change
in protease. By swapping one van der Waals hydrophobic contact for another,
hydrophobic residues slide over one another rearranging of the hydrophobic core of
protease (Figures 3.3 and 3.4). Such hydrophobic sliding within the core of a protein that
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facilitates a conformational change has not been previously elucidated. However, it may
represent a general mechanism for protein dynamics.
HIV-1 protease interacting with substrates or inhibitors is a dynamic process that
requires binding and release of a ligand. The interaction between the protease and the
substrate could be considered a more transient interaction as protease binds, cleaves the
substrate and releases the product. Inhibitor binding requires a more stable protease
capable of holding on to an inhibitor. Therefore mutations leading to a more dynamic
protease that can release inhibitors more quickly may cause resistance without impacting
catalytic activity. This may be an important mechanism by which mutations outside the
active site cause drug resistance.
Drug Resistance
Non-active site mutations in HIV-1 protease play important roles in the
development of drug resistance (Figure 2.1, Figure 3.1, Figure 4.1, and Table 3.1) (Shafer
et al. 1999). However, the mechanism by which these mutations exert their effect has not
yet been elucidated. This study has established interdependent roles in protein dynamics
and ligand binding for residues outside the active site. Residues within the hydrophobic
core of protease exchange van der Waal contacts, sliding past each other, and facilitating
the opening of the active site region for ligand binding. Mutations in the hydrophobic
core could alter the conformational range of protease by affecting these interactions. The
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selective pressure of inhibitor therapy would select for protease variants whose
conformational range allows for substrate cleavage but disrupts inhibitor binding. While
some residues within the hydrophobic core are highly conserved, those residues that do
mutate within the hydrophobic core usually mutate only to other hydrophobic residues
(Table 3.1), indicating that these hydrophobic interactions are necessary for protease
stability. Residues, such as Ile62, mutate more frequently when under the selective
pressure of inhibitor therapy. The most frequent mutation at this site is I62V, whose
smaller side chain would necessitate repacking of the hydrophobic core and affect the
available degrees of freedom for surrounding residues. This would likely alter the
conformational changes observed in these simulations. By altering the conformational
flexibility of the unliganded protease, mutations in the hydrophobic core could affect the
transition between the unliganded and liganded states of HIV-1 protease.
Similarly, mutations in the flap region that led to dramatic enthalpy and entropy
changes of inhibitor binding were proposed to alter the dynamic properties of the flap
region. The correlation between entropy and protein dynamics established in Chapter II
could be used to infer information about the drug resistant flap mutations examined in
Chapter IV. Ile54 does not directly contact substrates or inhibitors. In the unbound
protease it contacts residues in the P1-loop, such as Pro81, and in the bound protease it
contacts Ile50 of the other monomer. However, mutations at this site have been well
correlated with drug resistance and could have an indirect role in substrate and ligand
binding by altering van der Waal contacts with surrounding residues and changing the
dynamic properties of the unliganded and liganded protease. The role of these residues in
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protein dynamics and drug resistance may not be obvious from crystal structures. The
results of this study suggest that the design of protease inhibitors must take into account
the dynamic properties of protease that are altered by mutations.
While mutations outside the active site are known to cause drug resistance, the
mechanism of this effect has been unclear. Additionally, the development of drug
resistance mutations in HIV-1 protease at residues that are not in contact with each other
are often correlated, such as mutations at Ile54 and Gly48. In chapter IV these mutations
were shown to have cooperative effects that decreased the binding affinity and altered the
thermodynamic properties of binding to protease inhibitors. This work provides new
insight into how these mutations exert the effect. Through interdependent effects on
protease dynamics, mutations outside active site can affect the inhibitor binding. By
furthering our understanding of the role of protein dynamics in ligand binding, inhibitor
design can better mimic the interaction between protease and its substrates.
Future Directions
This study uses multiple biophysical methods, including ITC and MD, to examine
protein dynamics. By studying both wild type HIV-1 protease and mutant variants
experimentally and computationally, we are able to develop a comprehensive picture of
the role of non-active site residues in protein dynamics. These residues facilitate the
conformational changes necessary for ligand binding through complex cooperative
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interactions. Mutations at these sites affect the dynamic properties of proteins, and
directly impact ligand binding by affecting the mechanism by which the protein changes
conformation between the free and bound state. The results of this study indicate that
non-active site mutations cause drug resistance by altering protein dynamics. However,
these differences are still difficult to visualize.
Using MD simulations we could further examine the role of mutations in protein
dynamics. While we were able to infer from ITC that mutations at Gly48 and Ile54 affect
protein dynamics, MD simulations would provide more information about the impact of
these mutations on flap dynamics. Similar to chapter III, simulations could be run on
unliganded and liganded proteases containing the mutations in MDRI54V and MDRI54A.
We may discover differences in how these variants interact with different ligands by
studying simulations of liganded complexes with both substrates and inhibitors,
Additionally, we could further study the role of the hydrophobic core in protein dynamics
by performing MD simulations on protease variants with mutations in the hydrophobic
core. By looking for differences in the hydrophobic sliding in the core, we will further
our understanding of the role of these non-active site mutations. Currently, the best tool
for looking at protein dynamics in a single molecule is MD simulations . The results of
these simulations can then be used to guide future experiments.
The next generation of inhibitor design will have to examine the dynamic
properties of HIV-1 protease.  In chapter II, this study established a possible correlation
between loss of protein dynamics and loss of protein function that had not previously
been demonstrated. By fully understanding the role of protein dynamics in the
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development of drug resistance, we may one day develop inhibitors from which HIV
cannot escape. However, the future study of protein dynamics necessitates the
development of better methods.  To fully understand the molecular recognition event
between HIV-1 protease and its substrate, we need to be able to view the transition a
protein undergoes when binding a ligand in a single molecule.  Appreciating the role of
protein dynamics in molecular recognition will allow for the development of better
inhibitors that more accurately mimic the natural substrates of HIV-1 protease. Using this
information will we will be able to truly tackle the problem of drug resistance and realize
the development of a cure for HIV infection.
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APPENDIX A
When using ITC, the two measured values are the Ka and ∆H. Each of these values has an
error of the fit of the data provided by the Origin software. The average Ka and ∆H from a
series of ITC measurements is first calculated, along with the corresponding standard
error of the measurement. The standard error of the measurement is the standard
deviation divided by the square root of the number of measurements, N. The Kd, ∆G, and
∆S are then calculated based on these averages, according to the equations below. The
errors for these values are propagated from the error of the measurement of the Ka and
∆H according to the equations below.
1. Calculating a Weighted Average
a. A weighted average takes into account the “error of the fit” that is given to
you in the Origin software
b. To calculate the weighted average for Ka:
€ 
Ka =
Kai
σ ai
2∑
1
σ ai
2∑
where Kai is each individual Ka measurement and σai is the corresponding
error of the fit
c. To calculate the weighted average for ∆H:
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€ 
ΔH =
ΔHi
σΔHi
2∑
1
σΔHi
2∑

where ∆Hi is each individual ∆H measurement and σ∆Hi is the corresponding
error of the fit
2. Calculating the standard error of the measurement of Ka and DH
a. Each of these values is calculated as a standard error of the measurement
b. To calculate the standard error of the measurement of Ka:
€ 
σKa =
Kai −Ka( )
2
∑
N −1( )
N
where N is the number of measurements
c. To calculate the standard error of the measurement of ∆DH:
€ 
σ
ΔH =
ΔHi −ΔH( )
2
∑
N −1( )
N
where N is the number of measurements
3. Calculating Kd, ∆G, and –T∆S
a. These values should be determined from the average Ka and ∆H, not from
the individual measurements
b. To calculate Kd:
€ 
Kd =
1
Ka
c. To calculate ∆G:
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€ 
ΔG = −RT ln Ka( )
d. To calculate –T∆S:
€ 
−TΔS = ΔG −ΔH
4. Calculating the error of Kd and ∆G
a. These errors are dependant on the standard deviation of Ka and DH
b. To calculate the error of Kd:
€ 
σKd = Kd ×
σKa
Ka
c. To calculate the error of ∆G:
€ 
σΔG = RT ×
σKa
Ka
d. To calculate the error of T∆S:
€ 
σTΔS = (σΔH )
2 + (σKa )
2
